

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-K/A  
(Amendment No. 1)**

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the fiscal year ended December 31, 2025

or  
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File No. 001-37627

**WAVE LIFE SCIENCES LTD.**

(Exact name of registrant as specified in its charter)

Singapore  
(State or other jurisdiction of  
incorporation or organization)

98-1356880  
(I.R.S. Employer  
Identification No.)

7 Straits View #12-00, Marina One East Tower  
Singapore  
(Address of principal executive offices)

018936  
(Zip code)

Registrant's telephone number, including area code: +65 6236 3388  
Securities registered pursuant to Section 12(b) of the Act:

| Title of each class  | Trading<br>symbol | Name of each exchange<br>on which registered |
|--|-------------------|--|
| \$0 Par Value Ordinary Shares                                    | WVE               | The Nasdaq Global Market                     |
| Securities registered pursuant to Section 12(g) of the Act: None |                   |  |

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes  No

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

|                         |                                     |                           |                          |
|-------------------------|-------------------------------------|---------------------------|--------------------------|
| Large accelerated filer | <input checked="" type="checkbox"/> | Accelerated filer         | <input type="checkbox"/> |
| Non-accelerated filer   | <input type="checkbox"/>            | Smaller reporting company | <input type="checkbox"/> |
|                         |                                     | Emerging growth company   | <input type="checkbox"/> |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The aggregate market value of the registrant's voting and non-voting ordinary shares held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the ordinary shares were last sold as of the last business day of the registrant's most recently completed second fiscal quarter (June 30, 2025) was \$851,013,538.

The number of outstanding ordinary shares of the registrant as of April 7, 2026 was 192,353,438.

**DOCUMENTS INCORPORATED BY REFERENCE**

None.

## EXPLANATORY NOTE

This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of Wave Life Sciences Ltd. (the “Company,” “we,” “our,” “us” or “Wave”) for the fiscal year ended December 31, 2025, as originally filed with the Securities and Exchange Commission (the “SEC”) on February 26, 2026 (the “Original 10-K”). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the dates described in the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with our filings made with the SEC subsequent to the filing of the Original 10-K, as information in such filings may update or supersede certain information contained in this Amendment. As used in this Amendment, unless otherwise stated or the context otherwise indicates, references to “Wave,” the “Company,” “we,” “our,” “us” or similar terms refer to Wave Life Sciences Ltd. and our wholly owned subsidiaries. The Wave Life Sciences Ltd. and Wave Life Sciences Pte. Ltd. names, the Wave Life Sciences mark, PRISM and the other registered and pending trademarks, trade names and service marks of Wave Life Sciences Ltd. appearing in this Amendment are the property of Wave Life Sciences Ltd. This Amendment also contains additional trade names, trademarks and service marks belonging to Wave Life Sciences Ltd. and to other companies. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties. Solely for convenience, the trademarks and trade names in this Amendment are referred to without the ® and ™ symbols, but such reference should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

## SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Amendment contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Exchange Act, that relate to future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. In some cases, forward-looking statements are identified by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “goals,” “intend,” “likely,” “may,” “might,” “ongoing,” “objective,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will” and “would” or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements, other than statements of historical fact, about, among other things: our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and capital requirements; our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements; the success, progress, number, scope, cost, duration, timing or results of our research and development activities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for submission, review or approval of any regulatory filing; the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates; the potential benefits that may be derived from any of our product candidates; our strategies, prospects, plans, goals, expectations, forecasts or objectives; the success of our collaborations with third parties; any payment that our collaboration partners may make to us; our ability to identify and develop new product candidates; our intellectual property position; our commercialization, marketing and manufacturing capabilities and strategy; our ability to develop sales and marketing capabilities; our estimates regarding future expenses and needs for additional financing; our ability to identify, recruit and retain key personnel; our financial performance; developments and projections relating to our competitors in the industry; our liquidity and working capital requirements; the expected impact of new accounting standards; the impact of tariffs on our business and operations; and our expectations regarding the impact of any local and global health epidemics on our business, including our research and development activities, preclinical studies and clinical trials, supply of drug product, and our workforce.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Amendment, we caution you that these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance or achievements expressed or implied by any forward-looking statement to differ. These risks, uncertainties and other factors include, among other things, our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product

candidates; actions of regulatory agencies, including the recent workforce reductions implemented at various U.S. regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; and any impacts on our business as a result of or related to any local and global health epidemics, geopolitical conflicts, global economic uncertainty, the impact of tariffs and changes in economic policies, volatility in inflation, volatility in interest rates or market disruptions on our business, as well as other risks and uncertainties under the “Risk Factors” section of the Original 10-K and in other filings we make with the SEC.

Each forward-looking statement contained in this Amendment is based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

As a result of these factors, we cannot assure you that the forward-looking statements in this Amendment will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as representations or warranties by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. We caution you not to place undue reliance on any forward-looking statement.

In addition, any forward-looking statement in this Amendment represents our views only as of the date of this Amendment and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

WAVE LIFE SCIENCES LTD.

FORM 10-K/A

TABLE OF CONTENTS

|                        |   |           |
|------------------------|---|-----------|
| <b><u>PART III</u></b> |   | <b>1</b>  |
| Item 10.               | <a href="#"><u>Directors, Executive Officers and Corporate Governance</u></a>   | 1         |
| Item 11.               | <a href="#"><u>Executive Compensation</u></a>   | 9         |
| Item 12.               | <a href="#"><u>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u></a> | 25        |
| Item 13.               | <a href="#"><u>Certain Relationships and Related Transactions, and Director Independence</u></a>                      | 27        |
| Item 14.               | <a href="#"><u>Principal Accountant Fees and Services</u></a>   | 29        |
| <b><u>PART IV</u></b>  |   | <b>31</b> |
| Item 15.               | <a href="#"><u>Exhibits and Financial Statement Schedules</u></a>   | 31        |
| Item 16.               | <a href="#"><u>Form 10-K Summary</u></a>  | 34        |
|                        | <a href="#"><u>Signatures</u></a>   | 35        |

---

## PART III

### Item 10. Directors, Executive Officers and Corporate Governance.

#### Board of Directors

Pursuant to our Constitution, there is no maximum number of directors that may hold office at any time. Our Board of Directors (our “Board”) currently consists of nine members and each of our directors is elected annually. Our Constitution requires that each of our directors retire at each annual general meeting of our shareholders, and each retiring director is then eligible for re-election. Pursuant to the Companies Act 1967 of Singapore and our Constitution, our Board must have at least one director who is ordinarily resident in Singapore. Aik Na Tan is currently our Singapore resident director.

Set forth below are the names of our directors, their ages as of April 7, 2026, their offices in our Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which they hold or have held directorships during the past five years. In addition, information about the specific experience, qualifications, attributes or skills that led to our Board’s conclusion at the time of filing of this Amendment that each person listed below should serve as a director, is set forth below:

| Name                      | Age | Position/Title                                  |
|---------------------------|-----|---|
| Paul B. Bolno, M.D., MBA  | 52  | President, Chief Executive Officer and Director |
| Christian Henry           | 58  | Chair of the Board                              |
| Mark H. N. Corrigan, M.D. | 68  | Director  |
| Peter Kolchinsky, Ph.D.   | 49  | Director  |
| Adrian Rawcliffe          | 54  | Director  |
| Ken Takanashi             | 61  | Director  |
| Aik Na Tan                | 55  | Director  |
| Gregory L. Verdine, Ph.D. | 66  | Director  |
| Heidi L. Wagner, J.D.     | 61  | Director  |

**Paul B. Bolno, M.D., MBA** has served as our President and Chief Executive Officer since December 2013 and as a director since April 2014. Since May 2020, Dr. Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Since December 2024, Dr. Bolno has served as Chairman of the Board of Directors to ExpressionEdits, a privately-held biotechnology company, and since September 2025, has served as a director of Invivyd, Inc., a publicly-traded biopharmaceutical company. From June 2020 through March 2024, Dr. Bolno served on the board of directors of SQZ Biotechnologies, a publicly-traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining us, he served at GlaxoSmithKline plc from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development—Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Wellcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline’s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine. We believe that Dr. Bolno’s experience serving as our President and Chief Executive Officer since 2013, his medical degree and clinical training in cardiothoracic surgery, his business degree and experience evaluating life sciences companies in healthcare private equity, and his extensive business development and operating experience working in various roles at one of the world’s largest global healthcare companies qualify him to serve on our Board.

**Christian Henry** has served as a director since November 2016, and as Chair of our Board since October 2017. Mr. Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since September 2020, and has also served on its board of directors since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of directors of CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President,

Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. We believe he is qualified to serve on our Board and as our Chair because of his proven strengths in corporate strategy, finance and operations, along with his extensive experience leading various functions at one of the largest and most innovative genetic healthcare companies, and his experience as a board member, board committee member and chief executive officer of publicly-traded life sciences companies.

**Mark H. N. Corrigan, M.D.** has served as a director since September 2019. Dr. Corrigan currently serves on the board of directors of AstronauTx LLC, a privately-held company. Dr. Corrigan also serves as a Strategic Advisor to Ceretype Neuromedicine. Dr. Corrigan served as a member of the board of directors of Silver Creek Pharmaceuticals, Inc., a privately held company, from November 2024 to May 2025 and of Nabriva Therapeutics plc, a publicly traded commercial-stage biopharmaceutical company, from June 2021 to December 2023, and previously served on Nabriva's board of directors from June 2017 to May 2020. Dr. Corrigan also served as chairman of the board of directors of Elios Therapeutics, LLC, a privately-held development-stage immunoncology company. Dr. Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. ("Correvio"), from March 2019 to May 2020. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co-founder) from 2016 to March 2019. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia. We believe he is qualified to serve on our Board because of his extensive experience working with clinical-stage, publicly-traded biopharmaceutical companies as a board member, board committee member and chief executive officer, his medical degree and clinical training in psychiatry, and his clinical and regulatory expertise.

**Peter Kolchinsky, Ph.D.** has served as a director since January 2015. Dr. Kolchinsky is a founder and Managing Partner of RA Capital, a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, diagnostics, services and research tools, where he has worked since 2001. RA Capital is the investment manager of RA Capital Healthcare Fund, L.P. Dr. Kolchinsky has served as a member of the board of directors of ARS Pharmaceuticals Inc., a publicly-traded biopharmaceutical company, since August 2021, in addition to serving as a member of the board of directors of a number of privately-held companies. He is the founder and currently serves on the advisory board of the non-profit organization No Patient Left Behind. Dr. Kolchinsky previously served as a member of the board of directors of Forma Therapeutics Holdings, Inc., from December 2019 through October 2022, Dicerna Pharmaceuticals, Inc., from July 2013 to December 2019, Icosavax, Inc. from July 2021 to December 2023, Research Alliance Corporation I from April 2020 to June 2021, Research Alliance Corporation II from July 2020 to December 2022, and Synthorx, Inc., from May 2018 to January 2020, all of which were publicly-traded biopharmaceutical companies. Dr. Kolchinsky also leads RA Capital's engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup", and frequently writes and speaks on the future of biotechnology innovation. Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor's degree in Biology from Cornell University. We believe he is qualified to serve on our Board because of his scientific acumen, his strong reputation as a thought leader in the life sciences industry, his extensive experience investing in and forming, building and growing life sciences companies and mentoring their management teams, as well as his experience as an institutional investor and his experience serving as a board member, board committee member, and board observer of various publicly-traded and privately-held healthcare and life science companies.

**Adrian Rawcliffe** has served as a director since February 2017. Since January 2026, Mr. Rawcliffe has served as CEO-Partner and Chief Executive Officer of Etiome Inc., a privately-held biotechnology company. From September 2019 to November 2025, Mr. Rawcliffe served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc. ("Adaptimmune"), a clinical-stage biopharmaceutical company traded on The Nasdaq Global Select Market until November 2025. Mr. Rawcliffe also served on the board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune from 2016 to November 2025. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D

Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW). We believe he is qualified to serve on our Board because of his global operating and business leadership experience working in the biopharmaceutical industry, his experience as a board member, board committee member, chief financial officer and chief executive officer of publicly-traded biotechnology companies, and his extensive operating and corporate development experience working in various roles at one of the world's largest global healthcare companies.

**Ken Takanashi** has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd. ("SNBL") and its affiliates and currently serves as its Vice Chairman. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of SNBL, from 2012 to 2014. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly-traded and became a privately-held company and wholly-owned subsidiary of SNBL on June 8, 2023. Since 2020, Mr. Takanashi has served as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, in addition to serving as a member of the board of directors of a number of privately-held companies. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor's degree from the University of Tokyo and is a Chartered Public Accountant. We believe he is qualified to serve on our Board because of his extensive experience leading global research and development organizations in the biopharmaceutical industry, his experience forming, building and taking life sciences companies public, his experience serving as a board member and board committee member of various publicly-traded life sciences companies, his long-standing history with Wave, his close familiarity with our Japanese operations, and his business, financial and accounting credentials.

**Aik Na Tan** has served as a director since August 2020. Ms. Tan currently serves as Senior Vice-President (Administration) at Nanyang Technological University, Singapore ("NTU"), a position she has held since January 2020. From when she joined NTU in August 2016 to December 2017, she served as NTU's Chief Financial Officer. She also served as NTU's Chief Administrative Officer from April 2017 to December 2017 and as NTU's Vice-President (Administration) from January 2018 to December 2019. Prior to joining NTU, Ms. Tan served as Global Finance Transformation Leader & Managing Director of the Chemours Company Singapore Pte Ltd, a spin-off from DuPont, from 2015 to 2016. From 1994 to 2015, Ms. Tan held numerous global and regional leadership roles at DuPont in accounting, corporate treasury, six sigma, financial systems, supply chain, operations, financial and strategic planning, including various positions at DuPont Company (Singapore) Pte Ltd, most recently serving as the Chief Financial Officer of DuPont Titanium Technologies from November 2011 to February 2015. Ms. Tan began her professional career as a tax assistant at Price Waterhouse. Ms. Tan holds a Bachelor of Accountancy degree from the Nanyang Technological University, Singapore, and is a member of the Institute of Singapore Chartered Accountants. We believe she is qualified to serve on our Board because of her extensive experience as a chief financial officer and chief administrative officer, her broad operations experience working in Singapore corporations, her experience working on boards of directors and committees thereof, as well as her business, financial and accounting credentials.

**Gregory L. Verdine, Ph.D.** is one of our founders and has served as a director since July 2013. He was our President, Chief Executive Officer and Chief Scientific Officer from our inception through December 2013 and served as Chairman of our Board from July 2013 through September 2017. Since 1989, Dr. Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr. Verdine co-founded the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is the co-founder of Parabilis Medicines (formerly Fog Pharmaceuticals Inc.), a privately-held company, and served as President and Chief Executive Officer of the company from October 2015 to June 2023 and Vice Chairman of the Board of Directors from June 2023 to June 2024. Dr. Verdine serves as President and Chief Executive Officer and serves on the board of directors of LifeMine Therapeutics Inc., DoveTree Medicines LLC, and DoveTree Unus, Inc., privately-held companies. Since August 2024, Dr. Verdine has served as Executive Chair at Biggie Bio, LLC and as sole Director of wholly-owned subsidiary VidaVinci, Inc., both privately held companies. Since 2025, Dr. Verdine has served as the Executive Chair at RococoBio, LLC, and since 2024, as a board member of Stipple Bio, Inc. Dr. Verdine is a co-owner of Lola Advisors and serves as Managing General Partner of LoLa Capital Partners, a new modality venture capital fund, and also serves as a consultant at Yael Capital Management Ltd., as well as XtalPi, a publicly-traded company on the Hong Kong Stock Exchange. He is also the founder of Warp Drive Bio (merged into Revolution Medicines, Inc. (Nasdaq: RVMD)) and served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company's inception in 2012 until April 2016. Dr. Verdine founded Enanta Pharmaceuticals and served as a member of its board of directors from 1990 through its initial public offering in 2013. He has served as a Venture Partner at WuXi Healthcare Ventures, AppleTree Ventures, TPG Biotech and Third Rock Ventures, and he is currently a Venture Partner at Andreessen Horowitz. He has served on the Board of Scientific Counselors of the National Cancer Institute, and on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer

Center, and was a Senior Advisor to SNBL, Hofmann La Roche, Pfizer and Merck. Dr. Verdine is also a co-founder of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He has also served as a director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute. Dr. Verdine received his Ph.D. in Chemistry from Columbia University and completed postdoctoral work in Molecular Biology at the Massachusetts Institute of Technology and Harvard Medical School. We believe he is qualified to serve on our Board because of his expertise and deep knowledge of our technology as one of our co-founders and a co-inventor of our stereoprogrammable backbone chemistry, his expertise in new modality therapeutics, his expertise in the field of oligonucleotide therapeutics, and his long track record of founding, advising and leading multiple successful biopharmaceutical companies.

**Heidi L. Wagner, J.D.** has served as a director since September 2019. Ms. Wagner previously served as Global Head of Government Affairs at ElevateBio, LLC, a privately-held biopharmaceutical company, from March 2023 through October 2025. Ms. Wagner served as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., from 2018 through January 2021. Prior to joining Global Blood Therapeutics, Ms. Wagner served as Senior Vice President, Global Governmental Affairs and a member of the Executive Committee at Alexion Pharmaceuticals, Inc. from 2012 to 2018, and as Vice President, Global Government Affairs from 2009 to 2012. Ms. Wagner held the role of Senior Director of Government Affairs at Genentech, Inc. from 2000 to 2009, and as Director, Government Affairs from 1998 to 1999. Prior to that time, she served as Health Policy Director and Consultant at Healthcare Leadership Council, and in various roles at Epstein Becker & Green and Groom & Nordberg, and the U.S. House of Representatives. Ms. Wagner currently serves a board member of the non-profit organization No Patient Left Behind, in addition to serving as a member of the board of directors of the Lieber Institute for Brain Development, and as a member of the board of directors and as a Trustee for the University of Colorado Foundation. From 2015 to 2018, she also served as a member of the board of directors of the European Confederation of Pharmaceutical Entrepreneurs. Ms. Wagner earned a J.D. from George Mason University School of Law and received a Bachelor of Science in Journalism and Mass Communication from the University of Colorado. We believe she is qualified to serve on our Board because of her enterprise leadership experience and her extensive experience as a government affairs executive driving strategy for government policy, pricing, reimbursement and patient access for various biopharmaceutical companies, including leading the pricing and reimbursement strategy, and implementing the global compliance programs for leading rare disease biopharmaceutical organizations.

### **Committees of the Board of Directors and Meetings**

**Meeting Attendance.** During the fiscal year ended December 31, 2025, our Board held four meetings, and the various committees of the Board met a total of 15 times. No director attended fewer than 75% of the total number of meetings of the Board and of committees of the Board on which such director served during 2025. The Board has adopted a policy under which our directors make reasonable efforts to attend our annual general meetings of shareholders. As a Singapore company, we are required to prepare annual Singapore statutory audited financial statements (our “second annual audit”) and to deliver them to our shareholders in connection with our annual general meetings of shareholders. Our second annual audit can only be conducted following our first annual audit, which requires our preparation and filing of annual U.S. generally accepted accounting principles (GAAP) audited consolidated financial statements with the SEC. As a result, these multiple audits do not allow us to schedule our quarterly board meetings at the same time as our annual general meetings of shareholders and we typically hold our annual general meetings during the summertime.

**Audit Committee.** Our Audit Committee held six meetings during the fiscal year ended December 31, 2025. Our Audit Committee currently has four members: Mr. Rawcliffe (Chair), Dr. Corrigan, Mr. Henry, and Ms. Tan. Our Audit Committee’s role and responsibilities are set forth in the Audit Committee’s written charter and include the responsibility to retain and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee’s enumerated role and responsibilities include the review of annual financial statements and oversight of data privacy and cybersecurity matters, consideration of matters relating to accounting policy and internal controls, and review of the scope of annual audits.

Dr. Corrigan, Messrs. Henry and Rawcliffe, and Ms. Tan satisfy the current independence standards promulgated by the SEC and by The Nasdaq Stock Market, as such standards apply specifically to members of audit committees. The Board has determined that each member of the Audit Committee meets the financial literacy requirements of The Nasdaq Stock Market Rules and that each of Messrs. Henry and Rawcliffe and Ms. Tan qualifies as an “audit committee financial expert,” as the SEC has defined that term in Item 407 of Regulation S-K.

The Audit Committee’s written charter is publicly available on our website at [www.wavelifesciences.com](http://www.wavelifesciences.com).

**Compensation Committee.** Our Compensation Committee met four times during the fiscal year ended December 31, 2025. The Compensation Committee currently has three members: Mr. Henry (Chair), Mr. Rawcliffe, and Ms. Wagner. Our Compensation Committee’s role and responsibilities are set forth in the Compensation Committee’s written charter and include reviewing, approving and making recommendations regarding our compensation policies, practices and procedures to ensure that legal and fiduciary responsibilities of the Board are carried out and that such policies, practices and procedures contribute to our success. Our Compensation Committee also administers our 2021 Equity Incentive Plan, as amended on August 6, 2024, our 2014 Equity Incentive

Plan, as amended, and our 2019 Employee Share Purchase Plan, as amended. The Compensation Committee is responsible for determining the compensation of our executive officers.

Each member of the Compensation Committee qualifies as independent under the definition promulgated by The Nasdaq Stock Market.

The Compensation Committee's written charter is publicly available on our website at [www.wavelifesciences.com](http://www.wavelifesciences.com).

***Nominating and Corporate Governance Committee.*** Our Nominating and Corporate Governance Committee met two times during the fiscal year ended December 31, 2025. The Nominating and Corporate Governance Committee currently has three members: Ms. Wagner (Chair), Mr. Takanashi and Dr. Corrigan. The Nominating and Corporate Governance Committee's role and responsibilities are set forth in the Nominating and Corporate Governance Committee's written charter and include evaluating and making recommendations to the full Board as to the size and composition of the Board and its committees, evaluating and making recommendations as to potential candidates, and evaluating current Board members' performance, and overseeing our practices related to human capital management.

Each member of the Nominating and Corporate Governance Committee qualifies as independent under the definition promulgated by The Nasdaq Stock Market.

The Nominating and Corporate Governance Committee is responsible for identifying individuals qualified to serve as directors on our Board, consistent with criteria approved by the Board, and recommending the persons to be nominated for election as directors, except where we are legally required by contract, law or otherwise to provide third parties with the right to nominate.

The process followed by the Nominating and Corporate Governance Committee to identify and evaluate director candidates includes making requests to Board members and others for recommendations, holding meetings from time to time to evaluate biographical information and reviewing background material relating to potential candidates and interviews of selected candidates by members of the committee and the Board. The Nominating and Corporate Governance Committee is also authorized by its charter to retain search firms to identify director candidates. The qualifications, qualities and skills that the committee believes must be met by a committee-recommended nominee for a position on our Board are as follows:

- Nominees should have a reputation for integrity, honesty and adherence to high ethical standards.
- Nominees should have demonstrated business acumen, experience and ability to exercise sound judgments in matters that relate to our current and long-term objectives and should be willing and able to contribute positively to our decision-making process.
- Nominees should have a commitment to understand Wave and our industry and to regularly attend and participate in meetings of the Board and its committees.
- Nominees should have the interest and ability to understand the sometimes conflicting interests of our various constituencies, which include shareholders, employees, customers, governmental units, creditors and the general public, and to act in the interests of all shareholders.
- Nominees should not have, nor appear to have, a conflict of interest that would impair the nominee's ability to represent the interests of all of our shareholders and to fulfill the responsibilities of a director.
- Nominees shall not be discriminated against on the basis of race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. Diversity of thought, background and experience on our Board is highly valued and is actively considered in the nomination process as well as in the Board's annual performance evaluation.
- Nominees should generally be able to serve for at least five years before reaching the age of 70.

The Nominating and Corporate Governance Committee strives to achieve a balance of backgrounds, perspectives, and experiences on the Board and its committees. We believe that our current Board represents diversity of thought, background and most importantly, experience, which has and continues to serve us well as we grow and have transitioned from a preclinical to clinical-stage company and now to a late-stage development and commercial company. The Board and management seek out highly qualified candidates with diverse backgrounds, skills and experiences as part of each search they conduct for qualified directors and executive officers, respectively.

The Nominating and Corporate Governance Committee's written charter and our Corporate Governance Guidelines, which set forth our nominee requirements, are publicly available on our website at [www.wavelifesciences.com](http://www.wavelifesciences.com).

***Research and Development Committee.*** Our Research and Development Committee met three times during the fiscal year ended December 31, 2025. The Research and Development Committee currently has three members: Drs. Corrigan (Chair), Kolchinsky and Verdine. Our Research and Development Committee's role and responsibilities are set forth in the Research and Development

Committee's written charter and generally include assisting us in evaluating research, development and technology ("R&D") issues and decisions; reviewing and providing feedback to our R&D management on our current and planned R&D programs and initiatives; serving as a sounding board for our R&D organization on research and development matters; and identifying and discussing with the Board significant emerging scientific and clinical issues and trends.

#### **Procedures by which Shareholders may Nominate Directors**

The Nominating and Corporate Governance Committee shall review and evaluate information available to it regarding candidates proposed by shareholders and shall apply the same criteria, and shall follow substantially the same process in considering them, as it does in considering other candidates. The factors generally considered by the Nominating and Corporate Governance Committee are set out in our Corporate Governance Guidelines, which are publicly available on our website at <http://ir.wavelifesciences.com/> under the heading "Corporate Governance." If a shareholder wishes to nominate a candidate to be considered by the Nominating and Corporate Governance Committee for election as a director at our 2027 Annual General Meeting of Shareholders, it must give timely notice of the nomination in writing to our General Counsel not less than 45 days prior to the date that is one year following the date on which we first mail our proxy statement relating to our 2026 Annual General Meeting of Shareholders (the "2026 AGM"). All shareholder proposals should be marked for the attention of General Counsel, Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138.

#### **Compensation Committee Interlocks and Insider Participation**

None of the members of our Compensation Committee during the last fiscal year (which included Mr. Henry (Chair), Mr. Rawcliffe, and Ms. Wagner) was an officer or employee of our Company. During the last fiscal year, none of our executive officers served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our Board or Compensation Committee.

#### **Familial Relationships**

There are no familial relationships between any of our executive officers and directors.

#### **Board Leadership Structure and Role in Risk Oversight**

The positions of Chair of the Board and Chief Executive Officer of Wave are presently separate. We believe that separating these positions allows our Chief Executive Officer to focus on our day-to-day business operations and strategy, while allowing our Chair of the Board to lead the Board in its fundamental role of providing advice to, and independent oversight of, management. Our Board recognizes the time, effort and energy that the Chief Executive Officer is required to devote to their position in the current business environment, as well as the commitment required to serve as our Chair, particularly as the Board's oversight responsibilities continue to grow. Our Board also believes that this structure ensures a greater role for the independent directors in the oversight of Wave and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our Board. The Board retains the authority to modify this leadership structure as and when appropriate to best address our unique circumstances at any given time and to serve the best interests of our shareholders.

Our Board oversees the risk management activities designed and implemented by our management and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our Board executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees. The committees oversee and regularly report to our Board with respect to the risks delegated to them or when a matter rises to the level of a material or enterprise level risk. In addition, our Board receives regular reports from members of our management team and other personnel that include assessments and potential mitigation of the risks and exposures involved with their respective areas of responsibility. Some examples of these risks include matters relating to our operations, research and development efforts, clinical trials, manufacturing capabilities, financial position and liquidity, and our communications strategy.

Our Board delegates to the Audit Committee oversight of certain aspects of our risk management process. Specifically, the Audit Committee receives regular reports from members of senior management on areas of material risk to us, including operational, financial, legal, regulatory, strategic and reputational risks, and risks related to information technology, data privacy and cyber security. Our Compensation Committee assists the Board in fulfilling its oversight responsibilities with respect to the management of risks arising from our executive compensation policies, practices and goal setting, including whether such policies balance risk and reward appropriately, align with shareholder interests, and are consistent with best practices. Our Nominating and Corporate Governance Committee assists the Board in fulfilling its oversight responsibilities with respect to the management of risks associated with Board organization, membership and structure, succession planning for our directors and executive officers, corporate governance and human capital practices.

## Hedging and Pledging Policies

We maintain a policy that, among other things, prohibits all officers, including our executive officers, directors and employees from engaging in “hedging” transactions with respect to our ordinary shares. This includes short sales, hedging of share ownership positions, transactions in straddles, collars or other similar risk reduction or hedging devices, and transactions involving derivative securities relating to our ordinary shares. In addition, they are also prohibited from pledging our securities.

## Clawback Policy

On October 2, 2023, our Board adopted a Clawback Policy to comply with the new clawback rules and listing standards promulgated by the SEC and Nasdaq Stock Market, respectively. The Clawback Policy generally provides that we will seek to recover, in the event of a required accounting restatement, excess incentive compensation received by covered officers where that compensation is based on erroneously reported financial information, regardless of fault or misconduct.

## Insider Trading Policy

We have adopted a policy regarding trading by Company Personnel in our securities (the “Insider Trading Policy”) that applies to all “Company Personnel,” which includes our Board, officers, employees, consultants, contractors, and certain other covered persons of our Company and our subsidiaries. Our Insider Trading Policy governs the purchase, sale, and/or other disposition of our securities by all Company Personnel and is designed to promote compliance with insider trading laws, rules, and regulations and any applicable listing standards. The overarching requirement of our Insider Trading Policy is that all transactions in our securities by Company Personnel must be conducted pursuant to Rule 10b5-1 trading plans.

Although we have not adopted a formal policy governing the purchase, sale, and/or other disposition of our securities by the Company, as part of the oversight of risk, our Board, or one or more of its committees, approves any transaction, plan or arrangement by or with the Company with respect to our securities on a case-by-case basis, and as part of their procedures to review and approve any such transaction, plan or arrangement, our Board or committee consults with legal counsel to ensure compliance with applicable insider trading laws, rules and regulations, and listing standards. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to our Original 10-K.

## Shareholder Communications to the Board

Generally, shareholders who have questions or concerns or who wish to address questions regarding our business directly with the Board, or any individual director, should direct their questions in writing to [InvestorRelations@wavelifesci.com](mailto:InvestorRelations@wavelifesci.com). Communications will be distributed to the Board, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the communications. Items that are unrelated to the duties and responsibilities of the Board may be excluded, such as junk mail and mass mailings, resumes and other forms of job inquiries, surveys and solicitations or advertisements. In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any outside director upon request.

## Executive Officers

Set forth below is information as of April 7, 2026 regarding our executive officers who are not also directors. We have employment agreements with our executive officers and all of our executive officers are at-will employees.

| <u>Name</u>                 | <u>Age</u> | <u>Title</u>   |
|-----------------------------|------------|--|
| Christopher Francis, Ph.D.  | 48         | Senior Vice President, Corporate Development, Head of Emerging Areas |
| Erik Ingelsson, M.D., Ph.D. | 51         | Chief Scientific Officer   |
| Kyle Moran, CFA             | 55         | Chief Financial Officer  |
| Chandra Vargeese, Ph.D.     | 64         | Chief Technology Officer, Head of Platform Discovery Sciences        |
| Chris Wright, M.D., Ph.D.   | 60         | Chief Medical Officer  |

**Christopher Francis, Ph.D.** has served as our Senior Vice President, Corporate Development, Head of Emerging Areas since May 2017. During the period January 2017 to May 2017, Dr. Francis served as our Senior Vice President, Corporate Development & Portfolio Management. Prior to that, Dr. Francis served as our Vice President, Head of Business Development since April 2014. Prior to joining us, Dr. Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established GlaxoSmithKline’s Rare Disease Unit. Before GlaxoSmithKline, Dr. Francis was a health care private equity associate at Two River LLC from 2008 to 2009. Dr. Francis has served as a Member of the Investment Review Committee for WEHI Ventures in Australia since 2023. He began his career in pharmaceutical pricing and

reimbursement consulting at IMS Health. Dr. Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge.

**Erik Ingelsson, M.D., Ph.D.** has served as our Chief Scientific Officer since May 2024. Prior to joining us, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery; Senior Vice President of Genomic Sciences; and Senior Vice President of Human Genetics and Computational Biology at GSK during the period of January 2020 to May 2024. While at GSK, he led teams focused on a large-scale, industrialized approach to target discovery and validation across GSK's therapy areas, including respiratory, immunology and inflammation; oncology; and infectious diseases. In his roles, he brought together human genetics, computational biology, functional genomics, chemical biology, structural biology, and protein and cellular sciences to drive drug discovery and development. Prior to joining GSK, Dr. Ingelsson was Professor of Medicine at Stanford University from 2016 to 2019, where his lab used human genetics and functional genomics to discover novel biology and drug targets related to insulin resistance and related conditions, such as obesity, MASH, and cardiovascular disease. His work combined large-scale human genomics studies with in-depth preclinical validation work and an emphasis on cardiometabolic diseases. Dr. Ingelsson previously served as Professor of Molecular Epidemiology at Uppsala University, Sweden from 2013 to 2016, and as Professor of Cardiovascular Epidemiology from 2010 to 2012, and as Associate Professor of Epidemiology from 2008 to 2010 at Karolinska Institute, Sweden. Over his career, Dr. Ingelsson has served as scientific advisor and board member for multiple public and private companies. Dr. Ingelsson earned his M.D. and Ph.D. at Uppsala University, Sweden. He completed postdoctoral research at the Framingham Heart Study in Boston, Massachusetts, and held residency and fellowship in Family Medicine at Gävle and Uppsala, Sweden, after which he was a practicing clinician for over 10 years.

**Kyle Moran, CFA** has served as our Chief Financial Officer since December 2020. Prior to this appointment, Mr. Moran served as our Vice President, Head of Finance from July 2014 to August 2016; Vice President, Technical Operations from August 2016 to December 2017; Senior Vice President, Technical Operations, from December 2017 to November 2018; Senior Vice President, Operations and Business Analytics from November 2018 to January 2020; and most recently as Senior Vice President, Finance and Operations from January 2020 through his promotion to Chief Financial Officer in December 2020. Prior to joining us, Mr. Moran served as Chief Financial Officer and Chief Operating Officer of Veroha, Inc., an information assurance software company focused on electronic notary solutions, from 2010 to 2014. He was also a founding partner of Context Financial Services, LLC, a boutique consulting firm that provided interim CFO-services to start-up and middle market companies undergoing rapid expansion or needing expert financial counsel and worked there from 2006 to 2014. In addition, Mr. Moran held senior operational and financial roles at leading global financial services firms, including Zurich Scudder Investments, JPMorgan Chase and Putnam Investments. Mr. Moran holds a bachelor's degree in Economics from Boston College and attended the Lemberg Master's Program in International Economics and Finance at Brandeis University. Mr. Moran is a Chartered Financial Analyst.

**Chandra Vargeese, Ph.D.** has served as our Chief Technology Officer, Head of Platform Discovery Sciences since May 2020. During the period of August 2014 to April 2020, Dr. Vargeese served as Senior Vice President, Head of Drug Discovery. Before joining us, Dr. Vargeese served as Novartis' Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr. Vargeese led siRNA delivery in the RNA Therapeutics division at Merck & Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr. Vargeese joined Merck through its acquisition of Sirna Therapeutics ("Sirna"), where she was Vice President of Chemistry. Before Sirna, Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen (pegaptanib), an approved therapy for treating wet Age-Related Macular Degeneration (AMD). Dr. Vargeese earned a Ph.D. in Organic Chemistry at the Indian Institute of Science, Bangalore, India and completed post-doctoral work at the University of Rhode Island.

**Chris Wright, M.D., Ph.D.** has served as our Chief Medical Officer since May 2025. Before joining us, Dr. Wright served as Chief Medical Officer of gene therapy companies Ring Therapeutics, Inc. from February 2023 to May 2025 and AavantiBio, Inc. from May 2021 through its acquisition by Solid Biosciences Inc. in December 2022. From April 2019 to March 2021, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cycleron Therapeutics, Inc. ("Cycleron"), a publicly-traded spin-off from Ironwood Pharmaceuticals, Inc. ("Ironwood"), where he led global development functions across therapeutic areas. From March 2017 to April 2019, Dr. Wright served as Senior Vice President, Chief Development Officer of Ironwood. Prior to that, Dr. Wright served as Senior Vice President, Chief Medical Officer of Axcella Health Inc. and Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated, where he led global development functions across therapeutic areas. Dr. Wright has served on the board of directors of Alkermes plc, a global biopharmaceutical company, since May 2022. Dr. Wright was previously an Associate Professor of Neurology at Harvard Medical School and was a practicing neurologist at Brigham and Women's Hospital for 20 years. He previously served as a Scientific Advisor for Cycleron. Dr. Wright earned his A.B. in Biochemical Sciences from Harvard University, his M.D. in Medicine and Neuroscience from Harvard Medical School, his Ph.D. in Neuroanatomy from Vrije Universiteit in the Netherlands, and his MMSc. in Clinical Investigation from Harvard Medical School.

## CODE OF BUSINESS CONDUCT AND ETHICS

We have adopted a code of business conduct and ethics that applies to all of our employees, including our principal executive officer and principal financial and accounting officer. The text of the code of conduct and ethics is posted on our website at [www.wavelifesciences.com](http://www.wavelifesciences.com). Disclosure regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive officer or principal financial officer will be included in a Current Report on Form 8-K filed with the SEC within four business days following the date of the amendment or waiver, unless website posting or the issuance of a press release of such amendments or waivers is then permitted by the rules of The Nasdaq Stock Market.

### Item 11. Executive Compensation.

#### COMPENSATION DISCUSSION AND ANALYSIS

##### *Introduction*

In the paragraphs that follow, we have provided an overview and analysis of our compensation program and policies, the material compensation decisions we have made under those programs and policies, and the material factors that we considered in making those decisions. Following this section, you will find a series of tables containing specific information about the compensation earned or paid in the fiscal year ended December 31, 2025 to the following executive officers, who we will refer to throughout as our “named executive officers” or “NEOs”:

| <i>Name</i>                | <i>Principal Position</i>  |
|----------------------------|--|
| Paul B. Bolno, M.D., MBA   | President and Chief Executive Officer                                |
| Christopher Francis, Ph.D. | Senior Vice President, Corporate Development, Head of Emerging Areas |
| Kyle Moran, CFA            | Chief Financial Officer  |
| Chandra Vargeese, Ph.D.    | Chief Technology Officer, Head of Platform Discovery Sciences        |

At our 2025 Annual General Meeting (“2025 AGM”), our shareholders approved, on an advisory basis, the compensation of the NEOs, as disclosed in the proxy statement for that meeting, pursuant to the compensation disclosure rules of the SEC. The proposal was supported by over 99% of the total votes cast. Our Compensation Committee reviewed the advisory vote results and, based on the strong level of support, determined that no significant changes to our executive compensation program were necessary at that time. Our Compensation Committee will continue to monitor and evaluate our executive compensation program going forward in light of our shareholders’ views and our transforming business needs. Our Compensation Committee expects to continue to consider the outcome of our say-on-pay votes and our shareholders’ views when making future compensation decisions for the NEOs.

##### *Executive Compensation Philosophy*

Our Compensation Committee regularly reviews the elements of the individual compensation packages for our Chief Executive Officer and our other executive officers to achieve the following primary objectives:

- Attract, retain and motivate superior executive talent across all areas of our business;
- Provide incentives that reward the achievement of performance goals that directly correlate to the enhancement of shareholder value, which we seek to achieve through the discovery, development and potential commercialization of transformative medicines;
- Ensure the majority of compensation is performance-based and “at-risk”; and
- Align our executive officers’ interests with those of our shareholders through long-term incentives linked to specific performance.

We aim for simplicity in our compensation program so that it is easy for our employees and our shareholders to understand the various components of the program and the incentives designed to drive our Company performance. The three key components of our executive compensation program are base salary, annual cash performance-based incentives and equity-based long-term incentive awards.

##### *2025 Business Highlights*

In 2025, we delivered on multiple key milestones across our pipeline, platform and our business, elucidating the potential of our best-in-class platform to advance transformative medicines. Highlights of our accomplishments and milestones that informed the annual performance-based cash incentive component of our executive compensation program are described below.

- *Obesity* -- Executed our WVE-007 development strategy on time and on budget by achieving first person dosed in our Phase 1 clinical trial for obesity (INLIGHT); fully enrolling INLIGHT study putting us on track to deliver periodic data updates beginning in 2025; advancing INLIGHT to deliver safety and Activin E data for presentation at Research Day; receiving acceptance of IND to commence INLIGHT in the U.S. in addition to other jurisdictions; accelerating INLIGHT to enable substantial positive interim readout in December 2025 thereby catalyzing Wave's largest financing to date, which enabled acceleration of development for WVE-007 and extended runway.
- *Alpha-1 antitrypsin deficiency* -- Executed our WVE-006 development strategy on time and on budget by executing on the RestorAATion-2 clinical trial of Pi\*ZZ AATD patients; delivered data for 200mg single dose and multidose cohorts and the 400mg single dose cohort.
- *Duchenne muscular dystrophy* -- Executed our WVE-N531 development strategy on time and on budget by delivering positive FORWARD-53 (48-week) data that demonstrated highly consistent dystrophin expression, best-in-class muscle delivery, multiple indicators of improved muscle health, and safe and well-tolerated profile. Commenced numerous activities to support 2026 NDA filing, including Part C of FORWARD-53 clinical trial and continued regulatory interactions. FDA approved IND for Part C of FORWARD-53 clinical trial; Fast Track Designation received.
- *Huntington's disease* -- Executed our WVE-003 development strategy on time and on budget by completing a potentially registrational Phase 2/3 study design, including incorporation of FDA feedback. Prepared an IND application for the Phase 2/3 study with plans to submit it in conjunction with a prospective strategic partner.
- *Discovery and preclinical pipeline* -- Selected new clinical candidates; prioritized PNPLA3 as the next clinical program, accelerated preclinical development of PNPLA3 for CTA filing in 2026. Shared pre-clinical data at Research Day demonstrating substantial progress in siRNA and AIMER delivery to adipose, muscle, kidney, lung, pancreas and peripheral nerve, as well as initial progress on blood-brain-barrier delivery. Leveraged our learnings from our platform and chemistry optimization to develop new bifunctional modalities which combine RNAi and RNA editing or dual RNAi silencing into a single oligonucleotide construct designed to silence multiple targets or silence one target while simultaneously editing or upregulating another distinct target.
- *GSK collaboration* -- Advanced our strategic collaboration with GSK by advancing multiple programs and earning milestones in connection therewith. Achieved proof of mechanism milestone for WVE-006. Advanced GSK collaboration programs to program initiation stage for certain programs; completed target validation stage for other programs; initiated new target validation programs for additional programs; and completed critical technology transfer for certain candidate programs.
- *Publications* -- Executed on publication strategy by publishing new manuscripts, submitting additional new manuscripts and providing oral presentations during 2025.
- *Resourced for sustainability* -- Conducted largest equity financing in Wave's history by raising gross proceeds of approximately \$402.5 million in our December 2025 marketed underwritten public offering, which was catalyzed by our delivery of positive interim data from our INLIGHT trial, thereby extending our cash runway into the third quarter of 2028.
- *Human capital* -- Implemented a talent and organization strategy designed to drive our distinctive culture and support our next potential evolutions while adding key, critical, high-caliber talent and maintaining low regrettable attrition.
- *Fiscal responsibility* -- We ended 2025 with \$602.1 million in cash and cash equivalents. During 2025, we further enhanced our internal cGMP manufacturing capabilities to increase control and visibility of our drug substance supply chain and leveraged these capabilities to nimbly and efficiently accelerate our clinical trials in a manner that enabled our achievement of the substantial milestones described above. Actively managed spend and delivered well beyond our 2025 corporate goals within our 2025 budget.

### *Roles and Responsibilities in the Decision-making Process*

#### *Role of the Compensation Committee*

Pursuant to its charter, our Compensation Committee creates the policies that govern base salary, annual cash performance-based incentives, our long-term incentive program and other compensation and benefits for our executive officers. Our Compensation Committee also oversees various executive and employee compensation plans and programs and is responsible for monitoring these plans and programs to confirm that they adhere to our compensation philosophy and objectives. Our Compensation Committee determines the appropriate compensation levels for our executive officers, evaluates officer and director compensation plans, policies and programs, and reviews benefit plans for our executive officers. Our Compensation Committee believes that the total compensation paid to our executive officers should be fair, reasonable and competitive, and that a significant portion of the total compensation should be tied to our Company's annual and long-term performance. Each year, our Compensation Committee reviews and discusses our executive officers' proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. The Chief Executive Officer's compensation is determined solely by the Compensation Committee.

### *Role of Management*

Our Compensation Committee works with members of our management, including our Chief Executive Officer (except with respect to his own compensation), and our human resources, finance and legal professionals. Typically, our management assists the Compensation Committee by providing information on corporate and individual performance and management's perspective and recommendations on compensation matters for each executive officer. Our Chief Executive Officer provides recommendations to the Compensation Committee regarding most compensation matters, including executive compensation and our annual and long-term incentive programs. However, the Compensation Committee does not delegate any of its functions to others in setting the compensation of our NEOs.

### *Role of Compensation Consultant*

Our Compensation Committee has the authority to retain the services and obtain the advice of external advisors, including compensation consultants, legal counsel and other advisors to assist in the evaluation of executive officer compensation. Our Compensation Committee engaged Aon Consulting Inc. ("Aon"), through its Human Capital Solutions, a division of Aon plc., and an independent executive compensation consulting firm, to review our executive compensation policies and practices and to conduct an executive compensation market analysis.

For 2025, Aon reviewed and advised on all principal aspects of our executive compensation program, including:

- Assisting in developing a peer group of publicly traded companies to be used to help assess executive compensation;
- Assisting in developing a competitive compensation strategy and consistent executive compensation assessment practices relevant to a public company, including review and recommendation of the annual performance-based cash incentive program as well as the equity strategy for the Company covering dilution, grant levels and type of equity; and
- Meeting with the Compensation Committee to review elements of executive compensation including the competitiveness of the executive compensation program.

Our Compensation Committee has assessed the independence of Aon consistent with The Nasdaq Stock Market listing requirements and has concluded that the engagement of Aon does not raise any conflicts of interest.

### *Peer Companies and Use of Market Data*

In determining market competitiveness of executive officer compensation, our Compensation Committee, with the assistance of its independent compensation consultant, Aon, evaluates the market competitiveness of compensation for each of our executive officers in order to guide target compensation decisions for the coming year. Our Compensation Committee references a peer group of publicly traded companies in the biotechnology/biopharmaceutical industry for purposes of gathering data to compare with our existing executive compensation levels and practices and as context for future compensation decisions. Our Compensation Committee reviews and updates the compensation peer group each year, as appropriate, to include companies that the Compensation Committee believes are similar in therapeutic focus, market capitalization, number of employees, structure, financial profile and geographic proximity to the Cambridge biotech cluster, as applicable. We also recognize that it is unlikely for companies to align equally on all factors, so we consider companies that meet a majority of the criteria. Due to the nature of our business, we compete for executive talent with many companies much larger than we are. Our Compensation Committee considers peer group and other industry compensation data and the recommendations of our compensation consultant when making decisions related to executive compensation, ultimately giving consideration to the competitiveness of our compensation program, internal perceptions of equity and individual performance and role.

In October 2024, our Compensation Committee determined that our peer group for purposes of setting 2025 executive compensation would consist of the following 15 companies that were selected among publicly traded biopharmaceutical companies:

- Alector, Inc.
- Arcturus Therapeutics Holdings, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Avidity Biosciences, Inc.
- Beam Therapeutics, Inc.
- Denali Therapeutics, Inc.
- Dyne Therapeutics, Inc.
- Editas Medicine, Inc.
- Intellia Therapeutics, Inc.
- Ionis Pharmaceuticals, Inc.
- Prime Medicine, Inc.
- PTC Therapeutics, Inc.
- Stoke Therapeutics, Inc.
- UniQure N.V.
- Verve Therapeutics, Inc.

Our Compensation Committee finds comparative data from our peer group to be useful in setting and adjusting executive compensation, but it does not target our programs or any particular element of compensation to be at or within a particular percentile

or range compared to our peers. Our Compensation Committee uses the peer group data primarily to ensure that our executive compensation program and its constituent elements are and remain competitive in relation to our peers, and applies judgment and discretion in establishing targeted compensation levels taking into account not only competitive market data but also the experience of the executive, scope of responsibility, critical skill sets and expertise.

#### *Pay Practices*

In evaluating, designing and implementing our executive compensation program, the Compensation Committee considers the latest industry trends in compensation governance and compensation best practices. As a result of our review of our executive compensation program, we have adopted a number of best practices that we believe reflect the high standards our Compensation Committee seeks to attain to support our compensation philosophy.

##### Pay practices we use:

- *Independent directors* - Our Compensation Committee is comprised of all independent directors.
- *Annual compensation review* - Our Compensation Committee undertakes a comprehensive review of compensation of our executives, including our named executive officers, on an annual basis.
- *Independent compensation consultant* - Our Compensation Committee engages its own compensation consultant and reviews its independence from management.
- *Avoids inappropriate risk-taking* - We review the structure of our executive compensation program to minimize the risk of inappropriate risk-taking by our executive officers.
- *Multi-year vesting* - The equity awards granted to our executive officers generally vest over multi-year periods, consistent with current market practice and our retention objectives.
- *Robust clawback policy* - Our Clawback Policy complies with SEC and Nasdaq rules requiring recovery from certain officers of erroneously awarded incentive compensation in the event of a covered restatement of our financial statements.

##### Pay practices we do NOT use:

- Reprice share options and other awards without shareholder approval.
- Allow employees or Board members to engage in short sales, purchasing or pledging our ordinary shares on margin, or entering into any hedging, derivative, or similar transactions.
- Provide excessive tax gross-ups.
- Provide excessive perquisites (perquisites are limited to those with a clear business-related rationale).
- Repurchase underwater share options.
- Award mega-grants, discounted share options, in-the-money share options or immediately vested equity.

#### *Components of Executive Compensation*

The primary elements of our executive compensation program are:

- Base salary;
- Annual performance-based cash incentive compensation; and
- Long-term equity incentive awards.

We also provide broad-based health and welfare benefits and have certain severance and change-in-control benefits. Our intention is to structure these components of our executive compensation program in a way that achieves the objectives of the program of linking and emphasizing pay to performance over both the short- and long-term, aligning executives' interests with the interests of shareholders and attracting, motivating and retaining highly skilled and experienced executives.

#### *Base Salary*

Annual base salary is designed to provide a competitive fixed rate of pay, recognizing different levels of responsibility and performance. Actual salaries reflect the judgment and consideration of numerous factors by the Compensation Committee. These factors include the NEO's experience, importance of position, expected future contributions, performance, comparative survey data, internal pay equity, scope of responsibilities, expertise, the criticality of the NEO's position within the Company, the other elements of

compensation received by the NEO, and the NEO's compensation in comparison to similarly situated executive officers at comparable companies in our peer group.

The salary increases for 2025 for all of our NEOs were made to ensure better alignment with market data and in consideration of internal pay equity.

The following were the annual base salaries of our NEOs in effect for 2024 and 2025:

| Name                       | 2024<br>Base Salary | 2025<br>Base Salary | % Increase |
|----------------------------|---------------------|---------------------|------------|
| Paul B. Bolno, M.D., MBA   | \$ 655,500          | \$ 700,000          | 6.7%       |
| Christopher Francis, Ph.D. | \$ 438,300          | \$ 451,400          | 3%         |
| Kyle Moran, CFA            | \$ 497,200          | \$ 520,100          | 4.6%       |
| Chandra Vargeese, Ph.D.    | \$ 487,540          | \$ 502,200          | 3%         |

#### *Annual Performance-Based Cash Incentive Compensation*

The Compensation Committee believes that, in order to reward performance and overall Company success, a portion of an executive officer's compensation should be tied to the achievement of the Company's goals in the form of an annual cash incentive payment. Our executive officers are eligible to receive annual cash incentive awards, with the target bonus opportunity determined as a percentage of their base salary. We established this program in order to focus and incentivize our executives to achieve short-term strategic business objectives.

For 2025, the target bonus opportunity for each NEO was the same as for 2024.

Our executive officers are eligible to receive annual cash incentive awards, with the target bonus opportunity for 2025 determined as a percentage of their base salary. At the end of 2024, our Board approved ambitious corporate goals and objectives that our Compensation Committee then used to design our annual cash incentive program for 2025. Under this program, the Compensation Committee determined that the corporate goals would apply uniformly to all of our executive officers. Our 2025 corporate goals that were set by our Board to determine our 2025 corporate performance, plus our additional achievements that proved to be helpful or important to our operations during 2025, are described above in "Compensation Discussion and Analysis — 2025 Business Highlights."

Based on our Board's assessment and consideration of the relative weighting and importance of our goals, our Board determined that we achieved 135% of our 2025 corporate goals. The Compensation Committee then determined that bonuses for 2025 performance be paid to our NEOs based on these results.

In early 2026, our Chief Executive Officer and other NEOs were awarded their incentive payouts in connection with meeting the 2025 corporate goals at 135% of their incentive target amounts with the exception of Mr. Moran and Dr. Vargeese, who received 142% of the target incentive amount. The following table sets forth the cash bonus payments for 2025 performance:

| Name                       | Incentive Target Amount<br>(as a % of Base Salary) | Actual Award |
|----------------------------|--|--------------|
| Paul B. Bolno, M.D., MBA   | 65%  | \$ 614,250   |
| Christopher Francis, Ph.D. | 45%  | \$ 274,226   |
| Kyle Moran, CFA            | 45%  | \$ 331,759   |
| Chandra Vargeese, Ph.D.    | 45%  | \$ 320,341   |

#### *Long-Term Incentive Compensation*

We view long-term incentive compensation in the form of equity awards as a critical element of our executive compensation program. Our program is designed to reward demonstrated leadership and performance, align our executive officers' interests with those of our shareholders through sustained, long-term value creation while retaining and motivating our executive officers for future performance.

#### *2026 Long-Term Incentive Program*

In 2026, the long-term incentive component of the compensation of our NEOs remained a mix of share options and time-based restricted share units ("RSUs") to continue combining the retention and downside risk benefits inherent in RSUs with the shareholder-value-creation benefits inherent in share options, while mitigating the potential risk that may manifest itself through using a single type of award. The share options were granted to each of our NEOs by our Compensation Committee on February 5, 2026, at an exercise price of \$12.75 per share, and vest over a four year term, with 25% vesting on February 8, 2027, and the remainder vesting

quarterly thereafter. The RSUs were granted to each of our NEOs by our Compensation Committee on February 5, 2026 and vest annually in equal installments of 25% over a four-year term beginning on February 8, 2027.

#### *2025 Long-Term Incentive Program*

In 2025, the long-term incentive component of the compensation of our NEOs consisted of a mix of share options and time-based RSUs. We changed the type of awards granted to a mix of two types of equity awards to combine the retention and downside risk benefits inherent in RSUs with the shareholder-value-creation benefits inherent in share options, while mitigating the potential risk that may manifest itself through using a single type of award. The share options were granted to each of our NEOs by our Compensation Committee on February 4, 2025, at an exercise price of \$11.74 per share, and vest over a four year term, with 25% vesting on February 8, 2026, and the remainder vesting quarterly thereafter. The RSUs were granted to each of our NEOs by our Compensation Committee on February 4, 2025 and vest annually in equal installments of 25% over a four-year term beginning on February 8, 2026.

#### *2024 Long-Term Incentive Program*

In 2024, the long-term incentive component of the compensation of our NEOs consisted solely of share options. These share options were granted to each of our NEOs by our Compensation Committee on February 5, 2024, at an exercise price of \$3.87 per share, and vest over a four-year term, with 25% vesting on February 5, 2025, and the remainder vesting quarterly thereafter. The Compensation Committee determined to grant share options to best align employees, including NEOs, with investors' interests to build long-term shareholder value in our Company.

We have a broad-based equity compensation program designed to reward and motivate our employees, including our NEOs. Equity awards help align the interests of our NEOs and other employees with the long-term interests of our shareholders and provide an opportunity for employees to acquire an ownership interest in our Company. The granting of equity awards is also consistent with our compensation philosophy of attracting, retaining and motivating our NEOs to deliver sustainable long-term value and aligning the interests of our executives with those of our shareholders. In determining the size and type of equity awards to grant, our Compensation Committee considered evolving market practices, as well as the retentive value provided by our equity grants.

Our 2021 Equity Incentive Plan, as most recently amended on August 5, 2025 (the "2021 Plan"), allows for the grant of options, restricted share awards, RSUs, and other share or cash-based awards and dividend equivalent awards to employees, non-employee directors and consultants. Equity grants during the 2024, 2023, and 2022 fiscal years were made in the form of share options.

For the details regarding our 2025 equity awards, see the "2025 Fiscal Year Grants of Plan-Based Awards" table below.

#### *Employee Benefits and Perquisites*

Benefits offered to our NEOs serve a different purpose than do the other elements of total compensation. In general, they are designed to provide a safety net of protection against the financial catastrophes that can result from illness, disability or death and provide for some benefits upon retirement. Benefits offered to our NEOs are the same as those offered to the general employee population, except for the car service provided to our Chief Executive Officer, which is reflected in the "All Other Compensation" column in the "Summary Compensation Table" below. The Compensation Committee determined it is in the best interest of our Company to provide car service for our Chief Executive Officer in order to promote the efficient use of his work time for our Company and to provide safe transportation given the demands of his role, which often require the participation on conference calls during commuting hours, as well as extended work hours.

#### *401(k) Plan*

We maintain a defined contribution 401(k) plan that is intended to qualify under Section 401(k) of the Internal Revenue Code of 1986, as amended (the "Code"). In general, all of our U.S. employees, including our NEOs, are eligible to participate in the 401(k) plan. Under the 401(k) plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit, which was equal to \$23,500 in 2025, and to have the amount of such reduction contributed to the 401(k) plan. In addition, employees who turn age 50 before the end of the 2025 calendar year may also defer up to an additional \$7,500. Beginning in 2025, employees who turn ages 60 to 63 during the year are eligible for an increased 401(k) catch-up contribution limit of up to \$11,250. We currently match 50% of an employee's 401(k) contributions up to a maximum of 6% of the participant's includable compensation. Matching contributions are 100% vested upon completion of one year of service with our Company. Matching contributions made to each of our NEOs are included in the "Summary Compensation Table" below. We do not provide defined benefit retirement plans, post-retirement health coverage, or any other supplemental retiree benefits for our NEOs.

#### *Employee Share Purchase Plan*

The Wave Life Sciences Ltd. Employee Share Purchase Plan, as amended (“ESPP”), allows full-time and certain part-time employees to purchase the Company’s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning every January 15th and July 15th. Shares are purchased at a price equal to 85% of the lower of the fair market value of the Company’s ordinary shares on the first business day or the last business day of an offering period. As of December 31, 2025, there were 2,161,381 ordinary shares available for issuance under the ESPP.

#### *Employment Agreements and Severance Benefits with Our Named Executive Officers*

Each of our NEOs entered into an employment agreement with us in connection with the commencement of his or her employment. All employment agreements generally provide for at-will employment and that our NEOs are eligible to participate in employee benefit plans of general applicability to other employees, which we maintain from time to time.

#### ***Paul B. Bolno, M.D., MBA***

In May 2020, we entered into an amended and restated employment agreement with Dr. Bolno, pursuant to which he serves as our President and Chief Executive Officer. The employment agreement amends and restates the prior employment arrangement between us and Dr. Bolno. As of January 1, 2025, Dr. Bolno’s annual base salary was \$700,000 and the Compensation Committee established his annual target bonus percentage at 65% of his annual base salary, with the actual amount to be paid determined based on the achievement of annual performance milestones defined by our Board in its sole discretion. Effective January 1, 2026, the Compensation Committee approved an increase of Dr. Bolno’s annual base salary to \$740,000. In February 2026, in recognition of his 2025 performance supporting the achievement of our corporate goals, as discussed above, the Compensation Committee authorized a cash bonus for Dr. Bolno of \$614,250 that was equal to 135% of his 2025 target bonus. In addition, in February 2026, the Compensation Committee approved an award to Dr. Bolno of an option to purchase 1,000,000 of our ordinary shares and 165,000 RSUs under our 2021 Plan as a 2026 long-term incentive plan (“2026 LTIP”) award, with such options and RSUs vesting over a four-year period, with 25% vesting on the first anniversary of the date of grant and the remainder vesting quarterly thereafter.

Pursuant to Dr. Bolno’s employment agreement, if we terminate his employment without cause or if he terminates his employment for good reason, Dr. Bolno will be entitled to receive continued payment of his then-current annual base salary for 18 months following termination; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 18 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity prorated through the termination date. In addition, if a change of control occurs and within one year following the change of control Dr. Bolno is terminated without cause or if Dr. Bolno terminates his employment for good reason, he will be entitled to receive a lump sum cash payment equal to 18 months of his then-current annual base salary; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 18 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity. Pursuant to applicable equity agreements with Dr. Bolno, all unvested shares underlying outstanding options and RSUs that were granted to him on or after January 1, 2018 will become fully vested upon his termination without cause or for good reason within 12 months following a change of control. Receipt of the severance and change of control benefits described above is subject to execution of a release of claims against us and compliance with certain restrictive covenants following the termination of his employment.

#### ***Chris Francis, Ph.D.***

In November 2022, we entered into an amended and restated employment agreement with Dr. Francis, pursuant to which he serves as our Senior Vice President, Corporate Development, Head of Emerging Areas. The employment agreement amends and restates the prior employment arrangement between us and Dr. Francis. As of January 1, 2025, Dr. Francis’s annual base salary was \$451,400, and the Compensation Committee established his annual target bonus percentage at 45% of his annual base salary, with the actual amount to be paid determined based on the achievement of annual performance milestones defined by our Board in its sole discretion. Effective January 1, 2026, the Compensation Committee approved an increase of Dr. Francis’s annual base salary to \$465,000. In February 2026, in recognition of his 2025 performance supporting the achievement of our corporate goals, as discussed above, the Compensation Committee authorized a cash bonus for Dr. Francis of \$274,226 that was equal to 135% of his 2025 target bonus. In addition, in February 2026, the Compensation Committee approved an award to Dr. Francis of an option to purchase 232,500 of our ordinary shares and 38,750 RSUs under our 2021 Plan as a 2026 LTIP award, with such options and RSUs vesting over a four-year period, with 25% vesting on the first anniversary of the date of grant and the remainder vesting quarterly thereafter.

Pursuant to Dr. Francis’s employment agreement, if we terminate his employment without cause or if he terminates his employment for good reason, Dr. Francis will be entitled to receive continued payment of his then-current annual base salary for 12 months following termination; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity prorated through the termination date. In addition, if a change of control occurs and within one year following the change of control Dr. Francis is terminated without cause or if Dr. Francis terminates his employment for good reason, he will be entitled to receive a lump sum cash payment equal to 12 months of his then-current annual base salary; continued payment

of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity. Pursuant to applicable equity agreements with Dr. Francis, all unvested shares underlying outstanding options and RSUs that were granted to him on or after January 1, 2018 will become fully vested upon his termination without cause or for good reason within 12 months following a change of control. Receipt of the severance and change of control benefits described above is subject to execution of a release of claims against us and compliance with certain restrictive covenants following the termination of his employment.

***Kyle Moran, CFA***

In January 2021, we entered into an amended and restated employment agreement with Mr. Moran, pursuant to which he serves as our Chief Financial Officer. The employment agreement amends and restates the prior employment arrangement between us and Mr. Moran. As of January 1, 2025, Mr. Moran's annual base salary was \$520,100, and the Compensation Committee established his annual target bonus percentage at 45% of his annual base salary, with the actual amount to be paid determined based on the achievement of annual performance milestones defined by our Board in its sole discretion. Effective January 1, 2026, the Compensation Committee approved an increase of Mr. Moran's annual base salary to \$548,700. In February 2026, in recognition of his 2025 performance supporting the achievement of our corporate goals, as discussed below, the Compensation Committee authorized a cash bonus for Mr. Moran of \$331,759 that was equal to 142% of his 2025 target bonus. In addition, in February 2026, the Compensation Committee approved an award to Mr. Moran of an option to purchase 273,750 of our ordinary shares and 45,625 RSUs under our 2021 Plan as a 2026 LTIP award, with such options and RSUs vesting over a four-year period, with 25% vesting on the first anniversary of the date of grant and the remainder vesting quarterly thereafter.

Pursuant to Mr. Moran's employment agreement, if we terminate his employment without cause or if he terminates his employment for good reason, Mr. Moran will be entitled to receive continued payment of his then-current annual base salary for 12 months following termination; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity prorated through the termination date. In addition, if a change of control occurs and within one year following the change of control Mr. Moran is terminated without cause or if Mr. Moran terminates his employment for good reason, he will be entitled to receive a lump sum cash payment equal to 12 months of his then current annual base salary; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity. Pursuant to applicable equity agreements with Mr. Moran, all unvested shares underlying outstanding options and RSUs that were granted to him on or after January 1, 2018 will become fully vested upon his termination without cause or for good reason within 12 months following a change of control. Receipt of the severance and change of control benefits described above is subject to execution of a release of claims against us and compliance with certain restrictive covenants following the termination of his employment.

***Chandra Vargeese, Ph.D.***

In May 2020, we entered into an amended and restated employment agreement with Dr. Vargeese, pursuant to which she serves as our Chief Technology Officer, Head of Platform Discovery Sciences. The employment agreement amends and restates the prior employment arrangement between us and Dr. Vargeese. As of January 1, 2025, Dr. Vargeese's annual base salary was \$502,200, and the Compensation Committee established her annual target bonus percentage at 45% of her annual base salary, with the actual amount to be paid determined based on the achievement of annual performance milestones defined by our Board in its sole discretion. Effective January 1, 2026, the Compensation Committee approved an increase of Dr. Vargeese's annual base salary to \$540,000. In February 2026, in recognition of her 2025 performance supporting the achievement of our corporate goals, as discussed below, the Compensation Committee authorized a cash bonus for Dr. Vargeese of \$320,341 that was equal to 142% of her 2025 target bonus. In addition, in February 2026, the Compensation Committee approved an award to Dr. Vargeese of an option to purchase 273,750 of our ordinary shares and 45,625 RSUs under our 2021 Plan as a 2026 LTIP award, with such options and RSUs vesting over a four-year period, with 25% vesting on the first anniversary of the date of grant and the remainder vesting quarterly thereafter.

Pursuant to Dr. Vargeese's employment agreement, if we terminate her employment without cause or if she terminates her employment for good reason, Dr. Vargeese will be entitled to receive continued payment of her then-current annual base salary for 12 months following termination; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until she commences new employment; and the payment of a separation bonus equal to her then annual target bonus opportunity prorated through the termination date. In addition, if a change of control occurs and within one year following the change of control Dr. Vargeese is terminated without cause or if Dr. Vargeese terminates her employment for good reason, she will be entitled to receive a lump sum cash payment equal to 12 months of her then-current annual base salary; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until she commences new employment; and the payment of a separation bonus equal to her then annual target bonus opportunity. Pursuant to applicable equity agreements with Dr. Vargeese, all unvested shares underlying outstanding options and RSUs that were granted to her on or after January 1, 2018 will become fully vested upon her termination without cause or for good

reason within 12 months following a change of control. Receipt of the severance and change of control benefits described above is subject to execution of a release of claims against us and compliance with certain restrictive covenants following the termination of her employment.

### ***Other Provisions Applicable to Named Executive Officers***

In addition, as a condition of their employment, each of our NEOs has entered into a non-competition and non-solicitation agreement pursuant to which he or she has agreed not to compete with us for a period of 12 months following the termination of their employment with us. All agreements generally provide for at-will employment and that our NEOs are eligible to participate in employee benefit plans of general applicability to other senior executives, which we maintain from time to time.

For purposes of change of control benefits included in our employment agreements with our NEOs, change of control is defined as follows: (A) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) the sale or disposition by the Company of all or substantially all of the Company's assets in a transaction requiring shareholder approval.

### ***Risk Analysis of Our Compensation Plans***

Our Compensation Committee reviews the risks and rewards associated with our compensation programs. The programs are designed with features that mitigate risk without diminishing the incentive nature of the compensation. We believe our compensation programs encourage and reward prudent business judgment and appropriate risk-taking over the short term and the long term. Our Compensation Committee regularly evaluates the risks involved with our compensation programs and does not believe that any of our compensation programs create risks that are reasonably likely to have a material adverse effect on us now or in the future. Our Compensation Committee considered the compensation structure of the Company for its employees including executive officers, which is based on an annual salary, annual bonus (for bonus-eligible employees), and equity incentive compensation in the form of share options and RSUs. We do not believe that we offer any short-term incentives that would reasonably be expected to result in high-risk actions or conduct by our employees. For example, incentive compensation for executive officers in the form of an annual cash bonus are based on a predetermined formula and management objectives approved by our Compensation Committee. In addition, annual cash bonus payments are based upon a variety of performance metrics, thereby diversifying the risk associated with any single performance indicator. Accordingly, we believe that we have a balanced pay and performance program that does not promote undue or excessive risk taking.

### ***Policies and Practices Related to the Timing of Grants of Certain Equity Awards***

From time to time, we grant share options and RSUs to our employees, including our NEOs. We award new hire equity grants on or soon after a new hire's start date of employment with us. We also provide annual long-term incentive grants consisting of our share options and/or RSUs. Our process is to grant the annual long-term incentive awards on the date following the conclusion of our annual compensation cycle, as determined when the Chief Executive Officer and Chief Financial Officer approve all non-executive compensation. That specific date for Chief Executive Officer approval is set and determined in advance based on the entirety of the performance management and compensation cycles.

At a regularly scheduled meeting of our Board and Compensation Committee, which is typically held in December of each year, our Board and Compensation Committee have a long-standing practice of reviewing our results for the most recently completed fiscal year, and reviewing our financial plan and strategy for the upcoming fiscal year. At these meetings, the Compensation Committee also reviews the performance of our NEOs with the Chief Executive Officer and based on those reviews, approves the grant of cash bonuses and equity awards for each individual's performance (other than the Chief Executive Officer) on the most recently completed fiscal year and establish their salaries for the current fiscal year. The Compensation Committee, without the Chief Executive Officer present, recommends to the Board grants of cash bonuses and equity awards for the Chief Executive Officer on the most recently completed fiscal year and any change to the Chief Executive Officer's salary for the current fiscal year. After further reviews and discussions, the Board determines whether to approve the Compensation Committee's recommendations as to grants of cash bonuses and equity awards for the Chief Executive Officer on the most recently completed fiscal year and any change to the Chief Executive Officer's salary for the current fiscal year. The Compensation Committee considers whether there is any material nonpublic information ("MNPI") about us when determining the timing of grants and generally does not time grants of share options in relation to our public disclosure of MNPI. During the year ended December 31, 2025, we did not time the release of MNPI for the purpose of affecting the value of executive compensation, and none of our NEOs were awarded options with an effective grant date during any period beginning four business days before the filing or furnishing of a Form 10-Q, Form 10-K, or Form 8-K that disclosed material non-public information, and ending one business day after the filing or furnishing of such reports.

## COMPENSATION COMMITTEE REPORT

The Compensation Committee of our Board has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K, which appears elsewhere in this report, with our management. Based on this review and discussion, the Compensation Committee has recommended to our Board that the Compensation Discussion and Analysis be included in this report.

Members of the Wave Life Sciences Ltd. Compensation Committee:

Christian Henry (Chair)

Adrian Rawcliffe

Heidi Wagner

## EXECUTIVE OFFICER AND DIRECTOR COMPENSATION

### Summary Compensation Table

The following table shows the total compensation paid or accrued during the last three fiscal years ended December 31, 2025, 2024, and 2023 to (i) our President and Chief Executive Officer, (ii) our Chief Financial Officer, and (iii) our two next most highly compensated executive officers, who earned more than \$100,000 during the fiscal year ended December 31, 2025 and were serving as executive officers as of such date, as applicable. Collectively, these four individuals are our NEOs for purposes of this Amendment.

| Name and Principal Position  | Year | Salary<br>(\$) | Share<br>Awards<br>(\$) <sup>(1)</sup> | Option<br>Awards<br>(\$) <sup>(2)</sup> | Non-Equity<br>Incentive<br>Plan<br>Compensation<br>(\$) | All Other<br>Compensation<br>(\$) <sup>(3)</sup> | Total<br>(\$) |
|--|------|----------------|--|---|---|--|---------------|
| Paul B. Bolno, M.D., MBA<br><i>President and Chief Executive Officer</i>                                     | 2025 | 700,000        | 1,420,540                              | 9,506,300                               | 614,250   | 36,826   | 12,277,916    |
|  | 2024 | 655,500        | -                                      | 3,064,934                               | 532,600   | 19,266   | 4,272,299     |
|  | 2023 | 636,400        | -                                      | 2,744,529                               | 475,700   | 17,671   | 3,874,300     |
| Kyle Moran, CFA<br><i>Chief Financial Officer</i>  | 2025 | 520,100        | 493,080                                | 2,395,588                               | 331,759   | 12,822   | 3,753,349     |
|  | 2024 | 497,200        | -                                      | 1,128,914                               | 279,675   | 11,592   | 1,917,381     |
|  | 2023 | 471,300        | -                                      | 970,730                                 | 243,900   | 11,142   | 1,697,072     |
| Chandra Vargeese, Ph.D.<br><i>Chief Technology Officer, Head of Platform Discovery Sciences</i>              | 2025 | 502,200        | 434,380                                | 2,129,411                               | 320,341   | 14,064   | 3,400,396     |
|  | 2024 | 487,540        | -                                      | 1,099,134                               | 287,975   | 13,914   | 1,888,563     |
|  | 2023 | 473,340        | -                                      | 1,051,535                               | 245,000   | 13,464   | 1,783,339     |
| Christopher Francis, Ph.D.<br><i>Senior Vice President, Corporate Development and Head of Emerging Areas</i> | 2025 | 451,400        | 293,500                                | 1,435,451                               | 274,226   | 11,310   | 2,465,887     |
|  | 2024 | 438,300        | -                                      | 870,312                                 | 246,550   | 11,260   | 1,566,422     |
|  | 2023 | 425,500        | -                                      | 871,059                                 | 220,200   | 10,710   | 1,527,469     |

- (1) Amount represents the aggregate grant date fair value for the share awards identified, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 7 to the financial statements included in our Original 10-K.
- (2) Amounts represent the aggregate grant date fair value for the option awards identified, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 7 to the financial statements included in our Original 10-K.
- (3) For 2025, the amounts include 401(k) matching contributions of \$10,500 made to each of Drs. Bolno, Vargeese, and Francis and Mr. Moran, as well as the value of annual premiums paid by us with respect to a life insurance policy for the benefit of each of the NEOs. For 2025, the amount for Dr. Bolno also includes reimbursement of commuting expenses of \$16,018 and the related tax gross up of \$9,066.

### 2025 Fiscal Year Grants of Plan-Based Awards

The following table shows information regarding grants of non-equity incentive plan awards and grants of equity awards that we made during the fiscal year ended December 31, 2025 to each of our NEOs.

| Name                       | Grant Date | Estimated Future Payouts Under Non-Equity Incentive Plan Awards: Target (\$) <sup>(1)</sup> | All Other Share Awards: Number of Shares or Units (#) <sup>(2)</sup> | All Other Option Awards: Number of Securities Underlying Options (#) <sup>(3)</sup> | Exercise or Base Price of Option Awards (\$/Sh) <sup>(4)</sup> | Grant Date Fair Value of Share and Option Awards (\$) <sup>(5)</sup> |
|----------------------------|------------|---|--|---|--|--|
| Paul B. Bolno, M.D., MBA   | -          | 455,000   | -  | -   | -  | -  |
|                            | 2/4/2025   | -   | 121,000  | -   | -  | 1,420,540  |
| Kyle Moran, CFA            | 2/4/2025   | -   | -  | 1,000,000   | \$ 11.74   | 9,506,300  |
|                            | 2/4/2025   | 234,045   | 42,000   | -   | -  | 493,080  |
| Chandra Vargeese, Ph.D.    | 2/4/2025   | -   | -  | 252,000   | \$ 11.74   | 2,395,588  |
|                            | 2/4/2025   | 225,990   | 37,000   | -   | -  | 434,380  |
| Christopher Francis, Ph.D. | 2/4/2025   | -   | -  | 224,000   | \$ 11.74   | 2,129,411  |
|                            | 2/4/2025   | 203,130   | 25,000   | -   | -  | 293,500  |
|                            | 2/4/2025   | -   | -  | 151,000   | \$ 11.74   | 1,435,451  |

- (1) Represents the potential 2026 cash incentive bonus payouts assuming target achievement of corporate goals, based upon the NEO's cash incentive bonus target and base salary in effect on December 31, 2025. No minimum threshold amount or maximum amount beyond the target amount was established. See the column entitled "Non-Equity Incentive Plan Compensation" in the "Summary Compensation Table" for the cash incentive bonuses earned by the NEOs in 2025. See "Compensation Discussion and Analysis — Components of Executive Compensation — *Annual Performance-Based Cash Incentive Compensation*" for a description of the target amount applicable to each NEO.
- (2) Represents grants of RSUs made in 2025. Such awards vest annually in equal installments over a four-year period beginning on February 4, 2026, subject to such officer's continued service with us on each such vesting date.
- (3) Represents the grant of share options made in 2025. Such awards have a four-year vesting period, with 25% of the shares subject to the award vesting on February 4, 2026 and the remainder vesting quarterly in equal installments over the following 12 quarters, subject to such officer's continued service with us on each vesting date.
- (4) Represents the closing market price of our ordinary shares on the grant date.
- (5) Amounts represent the aggregate grant date fair value for the options and restricted share unit awards, as applicable, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 7 to the financial statements included in the Original 10-K.

#### Narrative to Summary Compensation Table

Our Compensation Committee creates the policies that govern base salary, annual cash performance-based incentives, our long-term incentive program and other compensation and benefits for our NEOs. Our Compensation Committee reviews and discusses our executive officers' proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. The Chief Executive Officer's compensation is determined solely by the Compensation Committee without the Chief Executive Officer present for the discussions.

In determining executive officer compensation, our Compensation Committee, with the assistance of its independent compensation consultant, Aon and an independent executive compensation consulting firm, evaluates the market competitiveness of compensation for each of our NEOs in order to guide target compensation decisions for the coming year. Our Compensation Committee references a peer group of publicly-traded companies in the biopharmaceutical industry for purposes of gathering data to compare with our existing executive compensation levels and practices and as context for future compensation decisions. Our Compensation Committee reviews and updates the compensation peer group each year, as appropriate, to include companies that the Compensation Committee believes are competitors for executive talent and that are similar to us in terms of their stage of development, therapeutic focus, market capitalization, number of employees, structure, financial profile and geographic proximity to the Cambridge biotech cluster, as applicable. We also recognize that it is unlikely for companies to align equally on all factors, so we consider companies that meet a majority of the criteria. Due to the nature of our business, we compete for executive talent with many companies much larger than we are. Our Compensation Committee considers peer group and other industry compensation data and the recommendations of our compensation consultant when making decisions related to executive compensation, ultimately giving consideration to the competitiveness of our compensation program, internal perceptions of equity and individual performance and role. Our Compensation Committee finds comparative data from our peer group to be useful in setting and adjusting executive compensation, but it does not target our programs or any particular element of compensation to be at or within a particular percentile or range compared to our peers. Our Compensation Committee uses the peer group data primarily to ensure that our executive compensation program and its constituent elements are and remain competitive in relation to our peers, and applies judgment and discretion in establishing targeted

compensation levels taking into account not only competitive market data but also the experience of the executive, scope of responsibility, critical skill sets and expertise. Our Compensation Committee retains flexibility to structure compensation based on good governance practices, our objectives of building our Company and creating value for our shareholders, and, most importantly, discovering, developing, and delivering life-changing treatments for people battling devastating diseases.

For a description of the employment arrangements with each of our NEOs, please refer to “Compensation Discussion and Analysis — *Employment Agreements and Severance Benefits with Our Named Executive Officers.*”

### **2021 Equity Incentive Plan**

Our 2021 Plan was most recently amended on August 5, 2025, following receipt of shareholder approval at our 2025 AGM to authorize an additional 8,000,000 ordinary shares, for an aggregate of 30,950,000 ordinary shares, for the granting of incentive options, non-qualified options (“NQSOs”), share appreciation rights and restricted share unit awards to our eligible employees and directors. The 2021 Plan serves as the successor to our 2014 Equity Incentive Plan, as amended (the “2014 Plan”), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be issued under the 2014 Plan after August 10, 2021. Any outstanding awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by us to satisfy any tax withholding obligation) on or after August 10, 2021 may be reissued under the 2021 Plan and any shares subject to an award that is canceled, forfeited or expires prior to exercise or realization, either in full or in part, under the 2021 Plan will again become available for issuance under the 2021 Plan. However, shares subject to an award under the 2021 Plan will not again be made available for issuance or delivery under the 2021 Plan if such shares are (a) shares tendered in payment of an option; (b) shares delivered or withheld by us to satisfy any tax withholding obligation; or (c) shares covered by a share-settled share appreciation right or other awards that were not issued upon the settlement of the award.

If we are acquired, our Board or Compensation Committee will with respect to share options and share appreciation rights: (i) make appropriate provision for the continuation of the share option or share appreciation right by substituting on an equitable basis for the ordinary shares then subject to such share option or share appreciation right either the consideration payable with respect to the outstanding ordinary shares in connection with the corporate transaction or securities of any successor or acquiring entity; (ii) cancel or arrange for the cancellation of the share options or share appreciation rights, to the extent not vested or exercised prior to the effective time of the transaction, in exchange for a payment in cash or ordinary shares as determined by our Board, in an amount equal to the amount by which the then fair market value of the ordinary shares subject to such vested share option or share appreciation right exceeds the exercise price; or (iii) after giving holders an opportunity to exercise to the extent vested their outstanding share options or share appreciation rights, terminate any or all unexercised share options and share appreciation rights at such time as the Board deems appropriate. If we are acquired, with respect to outstanding restricted share unit awards, our Board or Compensation Committee shall make appropriate provision for the continuation of such restricted awards on the same terms and conditions by substituting on an equitable basis for the ordinary shares then subject to such restricted awards either the consideration payable with respect to the outstanding ordinary shares in connection with the transaction or securities of any successor or acquiring entity. In lieu of the foregoing, if we are acquired, our Board may provide that, upon consummation of the acquisition, each outstanding restricted award shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such transaction to a holder of the number of ordinary shares comprising such restricted award to the extent then vested.

## Outstanding Equity Awards at 2025 Fiscal Year-End

The following table shows grants of options and unvested restricted share unit awards outstanding on the last day of the fiscal year ended December 31, 2025 to each of the NEOs.

| Name                       | Option Awards     |   |   |                            |                        | Share Awards                                       |   |   |   |      |
|----------------------------|-------------------|---|---|----------------------------|------------------------|--|---|---|---|------|
|                            | Option Grant Date | Number of Securities Underlying Unexercised Options Exercisable (#) | Number of Securities Underlying Unexercised Options Unexercisable (#) | Option Exercise Price (\$) | Option Expiration Date | Number of Shares or Units That Have Not Vested (#) | Market Value of Shares or Units That Have Not Vested (\$) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (\$) <sup>(7)</sup> |      |
| Paul B. Bolno, M.D., MBA   | 6/16/2016         | 236,400   | -   | \$ 18.79                   | 6/16/2026              | -  | -   | -   | \$ -  |      |
|                            | 1/25/2017         | 72,500  | -   | \$ 29.05                   | 1/25/2027              | -  | -   | -   | \$ -  |      |
|                            | 1/23/2018         | 109,000   | -   | \$ 40.05                   | 1/23/2028              | -  | -   | -   | \$ -  |      |
|                            | 3/3/2020          | 63,000  | -   | \$ 8.17                    | 3/3/2030               | -  | -   | -   | \$ -  |      |
|                            | 2/1/2021          | 200,000   | -   | \$ 10.48                   | 2/1/2031               | -  | -   | -   | \$ -  |      |
|                            | 1/1/2022          | 562,500   | 37,500 <sup>(1)</sup>   | \$ 3.14                    | 1/1/2032               | -  | -   | -   | \$ -  |      |
|                            | 7/25/2022         | 180,000   | -   | \$ 2.83                    | 7/25/2032              | -  | -   | -   | \$ -  |      |
|                            | 2/17/2023         | 530,062   | 240,938 <sup>(2)</sup>  | \$ 4.75                    | 2/17/2033              | -  | -   | -   | \$ -  |      |
|                            | 2/5/2024          | 441,262   | 567,338 <sup>(3)</sup>  | \$ 3.87                    | 2/5/2034               | -  | -   | -   | \$ -  |      |
|                            | 2/4/2025          | -   | 1,000,000 <sup>(4)</sup>  | \$ 11.74                   | 2/4/2035               | -  | -   | -   | \$ -  |      |
|                            |                   | -   | -   | \$ -                       | -                      | 90,750 <sup>(5)</sup>                              | 1,542,750   | 92,500 <sup>(6)</sup>   | \$ 1,572,500  |      |
|                            | Kyle Moran, CFA   | 6/16/2016   | 21,647  | -                          | \$ 18.79               | 6/16/2026  | -   | -   | -   | \$ - |
| 1/23/2018                  |                   | 15,000  | -   | \$ 40.05                   | 1/23/2028              | -  | -   | -   | \$ -  |      |
| 1/1/2022                   |                   | 64,062  | 10,938 <sup>(1)</sup>   | \$ 3.14                    | 1/1/2032               | -  | -   | -   | \$ -  |      |
| 2/17/2023                  |                   | 137,481   | 85,219 <sup>(2)</sup>   | \$ 4.75                    | 2/17/2033              | -  | -   | -   | \$ -  |      |
| 2/5/2024                   |                   | 162,531   | 208,969 <sup>(3)</sup>  | \$ 3.87                    | 2/5/2034               | -  | -   | -   | \$ -  |      |
| 2/4/2025                   |                   | -   | 252,000 <sup>(4)</sup>  | \$ 11.74                   | 2/4/2035               | -  | -   | -   | \$ -  |      |
|                            | -                 | -   | \$ -  | -                          | 31,500 <sup>(5)</sup>  | 535,500  | 15,000 <sup>(6)</sup>                                     | \$ 255,000  |   |      |
| Chandra Vargeese, Ph.D.    | 6/16/2016         | 49,600  | -   | \$ 18.79                   | 6/16/2026              | -  | -   | -   | \$ -  |      |
|                            | 1/25/2017         | 19,500  | -   | \$ 29.05                   | 1/25/2027              | -  | -   | -   | \$ -  |      |
|                            | 1/23/2018         | 35,000  | -   | \$ 40.05                   | 1/23/2028              | -  | -   | -   | \$ -  |      |
|                            | 3/3/2020          | 36,000  | -   | \$ 8.17                    | 3/3/2030               | -  | -   | -   | \$ -  |      |
|                            | 2/1/2021          | 50,000  | -   | \$ 10.48                   | 2/1/2031               | -  | -   | -   | \$ -  |      |
|                            | 1/1/2022          | 187,500   | 12,500 <sup>(1)</sup>   | \$ 3.14                    | 1/1/2032               | -  | -   | -   | \$ -  |      |
|                            | 7/25/2022         | 60,000  | -   | \$ 2.83                    | 7/25/2032              | -  | -   | -   | \$ -  |      |
|                            | 2/17/2023         | 203,087   | 92,313 <sup>(2)</sup>   | \$ 4.75                    | 2/17/2033              | -  | -   | -   | \$ -  |      |
|                            | 2/5/2024          | 158,243   | 203,457 <sup>(3)</sup>  | \$ 3.87                    | 2/5/2034               | -  | -   | -   | \$ -  |      |
|                            | 2/4/2025          | -   | 224,000 <sup>(4)</sup>  | \$ 11.74                   | 2/4/2035               | -  | -   | -   | \$ -  |      |
|                            |                   | -   | -   | \$ -                       | -                      | 27,750 <sup>(5)</sup>                              | 471,750   | 50,000 <sup>(6)</sup>   | \$ 850,000  |      |
| Christopher Francis, Ph.D. | 6/16/2016         | 37,100  | -   | \$ 18.79                   | 6/16/2026              | -  | -   | -   | \$ -  |      |
|                            | 1/25/2017         | 19,500  | -   | \$ 29.05                   | 1/25/2027              | -  | -   | -   | \$ -  |      |
|                            | 1/23/2018         | 26,000  | -   | \$ 40.05                   | 1/23/2028              | -  | -   | -   | \$ -  |      |
|                            | 1/1/2022          | -   | 9,375 <sup>(1)</sup>  | \$ 3.14                    | 1/1/2032               | -  | -   | -   | \$ -  |      |
|                            | 2/17/2023         | -   | 76,469 <sup>(2)</sup>   | \$ 4.75                    | 2/17/2033              | -  | -   | -   | \$ -  |      |
|                            | 2/5/2024          | -   | 161,100 <sup>(3)</sup>  | \$ 3.87                    | 2/5/2034               | -  | -   | -   | \$ -  |      |
|                            | 2/4/2025          | -   | 151,000 <sup>(4)</sup>  | \$ 11.74                   | 2/4/2035               | -  | -   | -   | \$ -  |      |
|                            | -                 | -   | \$ -  | -                          | 18,750 <sup>(5)</sup>  | 318,750  | 32,500 <sup>(6)</sup>                                     | \$ 552,500  |   |      |

(1) 25% vested on January 1, 2023 and the remainder vests in equal quarterly installments over the following 12 quarters, subject to such officer's continued service with us on each such vesting date. The award shall become fully vested upon termination without cause or for good reason within 12 months following a change of control.

- (2) 25% vested on February 17, 2024 and the remainder vests in equal quarterly installments over the following 12 quarters, subject to such officer's continued service with us on each such vesting date. The award shall become fully vested upon termination without cause or for good reason within 12 months following a change of control.
- (3) 25% vested on February 5, 2025 and the remainder vests in equal quarterly installments over the following 12 quarters, subject to such officer's continued service with us on each such vesting date. The award shall become fully vested upon termination without cause or for good reason within 12 months following a change of control.
- (4) 25% vests on February 4, 2026 and the remainder vests in equal quarterly installments over the following 12 quarters, subject to such officer's continued service with us on each such vesting date. The award shall become fully vested upon termination without cause or for good reason within 12 months following a change of control.
- (5) 25% vests on February 4, 2026 and the remainder vests in equal annual installments over the following three years, subject to such officer's continued service with us on each such vesting date. The award shall become fully vested upon a change of control.
- (6) On May 4, 2022, 50% of the 2019 performance-based RSUs vested upon the achievement of the PN chemistry milestone and of the shares listed, if prior to March 7, 2029 the regulatory approval milestone is achieved, 80% of the unvested performance-based RSUs will be earned and vest, and if the commercial sale milestone is achieved, 20% of the unvested 2019 performance-based RSUs will be earned and vest.
- (7) The market value of the 2019 Performance-Based RSUs is based on the closing price of our ordinary shares of \$17.00 per share at December 31, 2025.

### Option Exercises in 2025

The following table shows information regarding exercises of options to purchase our ordinary shares held by each of our NEOs during the fiscal year ended December 31, 2025.

#### Option Awards

| Name                       | Number of Shares<br>Acquired on Exercise<br>(#) | Value Realized<br>on Exercise<br>(\$) <sup>(1)</sup> |
|----------------------------|---|--|
| Paul B. Bolno, M.D., MBA   | 169,025   | \$ 1,196,605   |
| Kyle Moran, CFA            | 296,000   | \$ 3,285,321   |
| Chandra Vargeese, Ph.D.    | 137,754   | \$ 1,238,008   |
| Christopher Francis, Ph.D. | 441,031   | \$ 4,319,924   |

- (1) The value realized on the exercise of options was calculated by multiplying the number of options exercised on the applicable exercise date by the difference between the sale price of the shares and the exercise price of the options.

### Pension Benefits

We do not have any qualified or non-qualified defined benefit plans.

### Nonqualified Deferred Compensation

We do not have any nonqualified defined contribution plans or other deferred compensation plan.

### Employee Benefits

Our NEOs participate in employee benefit programs available to our employees generally, including medical and dental insurance, and a tax-qualified 401(k) plan.

### Potential Payments Upon Termination or Change-In-Control

The following table sets out the estimated potential payments upon termination or a change in control for each of our NEOs, based on the assumptions discussed above and assuming such event occurred on December 31, 2025, the last business day of 2025. In accordance with SEC rules, the potential payments were determined under the terms of our contracts, agreements, plans and arrangements as in effect on December 31, 2025. The tables do not include any previously vested equity awards or accrued benefits. Because the payments to be made to an NEO depend on several factors, the actual amounts to be paid out upon a triggering event can only be determined at the time of the triggering event.

| Name                       | Compensation Component                                   | Involuntary Not for Cause Termination (\$) | Voluntary for Good Reason Termination (\$) | Acceleration of Vesting Upon a Change of Control (\$) | Termination Without Cause or For Good Reason Within 12 Months Following a Change of Control (\$) |
|----------------------------|--|--|--|---|--|
| Paul B. Bolno, M.D., MBA   | Base Salary  | 1,050,000 <sup>(2)</sup>                   | 1,050,000 <sup>(2)</sup>                   | -   | 1,050,000 <sup>(2)</sup>   |
|                            | Non-Equity Incentive Plan Compensation                   | 455,000 <sup>(3)</sup>                     | 455,000 <sup>(3)</sup>                     | -   | 455,000 <sup>(3)</sup>   |
|                            | Acceleration of unvested options and RSUs <sup>(1)</sup> | -  | -  | 16,180,388  | 3,115,250  |
|                            | Benefits and Perquisites                                 | 56,575 <sup>(4)</sup>                      | 56,575 <sup>(4)</sup>                      | -   | 56,575 <sup>(4)</sup>  |
| Kyle Moran, CFA            | Base Salary  | 520,100 <sup>(6)</sup>                     | 520,100 <sup>(6)</sup>                     | -   | 497,200 <sup>(6)</sup>   |
|                            | Non-Equity Incentive Plan Compensation                   | 234,045 <sup>(3)</sup>                     | 234,045 <sup>(3)</sup>                     | -   | 223,740 <sup>(3)</sup>   |
|                            | Acceleration of unvested options and RSUs <sup>(1)</sup> | -  | -  | 5,264,816   | 790,500  |
|                            | Benefits and Perquisites                                 | 32,020 <sup>(5)</sup>                      | 32,020 <sup>(5)</sup>                      | -   | 32,020 <sup>(5)</sup>  |
| Chandra Vargeese, Ph.D.    | Base Salary  | 502,200 <sup>(6)</sup>                     | 502,200 <sup>(6)</sup>                     | -   | 487,540 <sup>(6)</sup>   |
|                            | Non-Equity Incentive Plan Compensation                   | 225,990 <sup>(3)</sup>                     | 225,990 <sup>(3)</sup>                     | -   | 219,393 <sup>(3)</sup>   |
|                            | Acceleration of unvested options and RSUs <sup>(1)</sup> | -  | -  | 5,153,715   | 1,321,750  |
|                            | Benefits and Perquisites                                 | 24,504 <sup>(5)</sup>                      | 24,504 <sup>(5)</sup>                      | -   | 24,504 <sup>(5)</sup>  |
| Christopher Francis, Ph.D. | Base Salary  | 451,400 <sup>(6)</sup>                     | 451,400 <sup>(6)</sup>                     | -   | 438,300 <sup>(6)</sup>   |
|                            | Non-Equity Incentive Plan Compensation                   | 203,130 <sup>(3)</sup>                     | 203,130 <sup>(3)</sup>                     | -   | 197,235 <sup>(3)</sup>   |
|                            | Acceleration of unvested options and RSUs <sup>(1)</sup> | -  | -  | 3,976,186   | 871,250  |
|                            | Benefits and Perquisites                                 | 37,717 <sup>(5)</sup>                      | 37,717 <sup>(5)</sup>                      | -   | 37,717 <sup>(5)</sup>  |

- (1) Value attributable to accelerated vesting of (i) then unvested options, determined by multiplying the number of shares accelerated by the difference between the exercise price of the option and the closing price of our ordinary shares on December 31, 2025, and (ii) then unvested RSUs, determined by multiplying the number of RSUs accelerated by the closing price of our ordinary shares on December 31, 2025.
- (2) Eighteen months of 2025 base salary continuation.
- (3) Target non-equity incentive compensation for 2025.
- (4) Payment of COBRA premiums for eighteen months based on executive's current benefits elections.
- (5) Payment of COBRA premiums for twelve months based on executive's current benefit elections.
- (6) Twelve months of 2025 base salary continuation.

For a further description of the employment agreements with our NEOs, including a summary of each NEO's severance and change in control benefits, please refer to "Compensation Discussion and Analysis - *Employment Agreements and Severance Benefits with Our Named Executive Officers.*"

#### Director Compensation

The following table shows the total compensation earned during the fiscal year ended December 31, 2025 by each of our non-employee directors. Directors who are also employees are not compensated for their service on our Board.

| Name                                   | Fees Earned or Paid in Cash (\$) <sup>(1)</sup> | Share Awards (\$) <sup>(2)</sup> | Option Awards (\$) <sup>(3)</sup> | Total (\$) |
|--|---|----------------------------------|-----------------------------------|------------|
| Christian Henry                        | 100,000   | 102,934                          | 362,666                           | 565,600    |
| Mark H. N. Corrigan, M.D.              | 74,375  | 102,934                          | 362,666                           | 539,975    |
| Peter Kolchinsky, Ph.D. <sup>(4)</sup> | 49,375  | 102,934                          | 362,666                           | 514,975    |
| Adrian Rawcliffe                       | 69,375  | 102,934                          | 362,666                           | 534,975    |
| Ken Takanashi                          | 49,375  | 102,934                          | 362,666                           | 514,975    |
| Aik Na Tan                             | 51,875  | 205,867                          | 732,191                           | 989,933    |
| Gregory L. Verdine, Ph.D.              | 49,375  | 102,934                          | 362,666                           | 514,975    |
| Heidi L. Wagner                        | 64,375  | 102,934                          | 362,666                           | 529,975    |

- (1) Amounts represent fees earned during 2025 under our Non-Employee Director Compensation Policy.
- (2) Amount represents the aggregate grant date fair value for the share awards identified, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 7 to the financial statements included in our Original 10-K.
- (3) Amount represents the aggregate grant date fair value for the option awards granted in 2025 to our non-employee directors, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 7 to the financial statements included in our Original 10-K.

- (4) Pursuant to the terms of the RA Capital Healthcare Fund, L.P. governing documents, Dr. Kolchinsky is required to remit to RA Capital Management, L.P. (“RA Capital”) both the cash and the equity compensation, and RA Capital and not Dr. Kolchinsky individually is the beneficial owner of such compensation.

The following table shows the aggregate number of shares subject to options held by each of our non-employee directors as of December 31, 2025:

| Name                      | Aggregate<br>Number of<br>Shares<br>Subject to<br>Options |
|---------------------------|---|
| Christian Henry           | 129,430   |
| Mark H. N. Corrigan, M.D. | 227,660   |
| Peter Kolchinsky, Ph.D.   | 216,430   |
| Adrian Rawcliffe          | 174,430   |
| Ken Takanashi             | 216,430   |
| Aik Na Tan                | 152,400   |
| Gregory L. Verdine, Ph.D. | 379,897   |
| Heidi L. Wagner, J.D.     | 213,660   |

## CEO Pay Ratio

Under rules adopted pursuant to the Dodd-Frank Act, we are required to calculate and disclose the total compensation paid to our median paid employee, as well as the ratio of the total compensation paid to the median employee as compared to the total compensation paid to our Chief Executive Officer (the “CEO Pay Ratio”). The paragraphs that follow describe our methodology and the resulting CEO Pay Ratio. The overall structure of our compensation and benefits programs are broadly similar across our organization, including a broad-based equity program pursuant to which all full-time employees receive equity, with differences reflecting the level of responsibility of the employees. For the purpose of determining the median employee, we included all our employees on December 31, 2025 located in the United States, which represented 95% of our employees globally (302 of our 317 global employees). We excluded our fifteen employees located outside the United States (twelve employees in England and three employees in Japan) as of December 31, 2025 under the SEC’s de minimis exception. Under the relevant rules, we are required to identify the median employee by use of a “consistently applied compensation measure” (“CACM”). We chose a CACM that closely approximates the annual target total direct compensation of our employees. Specifically, we identified the median employee by aggregating for each applicable employee as of December 31, 2025: (1) 2025 base salary or base rate of pay (annualized in the case of employees who were not employed for the full fiscal year), (2) target annual cash incentive award, and (3) grant date fair value of any equity awards granted during 2025 to reasonably reflect the annual compensation of our employees. After applying our CACM methodology, we identified the median employee. Once the median employee was identified, we calculated the median employee’s annual target total direct compensation in accordance with the requirements of the Summary Compensation Table.

We calculated the 2025 total compensation for our median employee of \$246,065 in the same manner we determine the total annual compensation of our NEOs for purposes of the Summary Compensation Table. Dr. Bolno’s 2025 total compensation as disclosed in the Summary Compensation Table was calculated to be \$12,277,916, of which \$10,926,840 represents the grant date fair value of equity awards, including options that vest over four years granted at an exercise price of \$11.74 representing \$9,506,300 of the equity value and RSUs that vest over four years representing \$1,420,540 of the equity value. As a result of the calculation, our CEO to median employee pay ratio for 2025 is 50:1. This information is being provided for compliance purposes and is a reasonable estimate calculated in a manner consistent with the SEC rules, based on our internal records and the methodology described above. The SEC rules for identifying the median compensated employee allow companies to adopt a variety of methodologies to apply certain exclusions and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Accordingly, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may use different methodologies, exclusions, estimates, and assumptions in calculating their own pay ratios. Neither our Compensation Committee nor our management used the CEO Pay Ratio measure in making compensation decisions.

## Non-Employee Director Compensation Policy

### *2025 Non-Employee Director Compensation Policy*

At our 2025 AGM, our shareholders approved our 2025 Non-Employee Director Compensation Policy, under which our non-employee directors are compensated for their service as directors, including as members of the various committees of our Board on which they serve, for the Board service period that commenced on the date of our 2025 AGM and runs through the date of our 2026 AGM. The terms of the 2025 Non-Employee Director Compensation Policy are as follows:

(A) Cash Compensation:

- Board of Directors: Annual cash compensation of \$45,000 to each non-employee director, other than the Chair of the Board, and cash compensation of \$75,000 to the non-employee Chair of the Board.
- Audit Committee: Additional annual cash compensation of \$20,000 to the Chair of the Audit Committee and \$10,000 to each member of the Audit Committee other than the Chair.
- Compensation Committee: Additional annual cash compensation of \$15,000 to the Chair of the Compensation Committee and \$7,500 to each member of the Compensation Committee other than the Chair.
- Nominating and Corporate Governance Committee: Additional annual cash compensation of \$15,000 to the Chair of the Nominating and Corporate Governance Committee and \$7,500 to each member of the Nominating and Corporate Governance Committee other than the Chair.
- Research and Development Committee: Additional annual cash compensation of \$15,000 to the Chair of the Research and Development Committee and \$7,500 to each member of the Research and Development Committee other than the Chair.
- Proration: Additional pro rata cash compensation of the annual cash compensation amounts set forth above shall be made, as applicable, to (i) any director who ceases to be a director, Chair of the Board or member or chair of any committee of the Board and (ii) any new non-employee director who is appointed by the Board, any independent director who is appointed to the position of Chair of the Board or chair of any such committee of the Board or any independent director who is appointed to serve on any such committee of the Board, for their services rendered as a director and/or committee member, for the portion of the year in which such director so served.

(B) Equity Compensation:

- Initial Equity Grant: One-time equity grant upon initial appointment or election to the Board of (i) an option to purchase 152,400 ordinary shares, which shall vest as to 12.5% of the shares on a quarterly basis during the two-year period following the grant date; and (ii) a restricted share unit of 25,400 ordinary shares, which shall vest as to 50% of the shares on the earlier of (x) the following year's annual general meeting of shareholders or (y) the following year's anniversary of the grant date, in each case during the two-year period following the grant date.
- Refresh Equity Grant: Each non-employee director whose initial equity grant has an expiration date within twelve months following the 2025 AGM shall be granted (i) an option to purchase 152,400 ordinary shares, which shall vest as to 12.5% of the shares on a quarterly basis during the two-year period following the grant date; and (ii) a restricted share unit of 25,400 ordinary shares, which shall vest as to 50% of the shares on the earlier of (x) the following year's annual general meeting of shareholders or (y) the following year's anniversary of the grant date, in each case during the two-year period following the grant date.
- Annual Equity Grant: Annual equity grant of (i) an option to purchase 76,200 ordinary shares, which shall vest as to 100% of the shares on the earlier of the 2026 AGM or the first anniversary of the grant date; and (ii) a restricted share unit of 12,700 ordinary shares, which shall vest as to 100% of the shares on the earlier of the 2026 AGM or the first anniversary of the grant date.
- Limitation on Equity Grants: A non-employee director shall be eligible to receive only one type of option grant at the 2025 AGM, which shall be an initial equity grant, a refresh equity grant, or an annual equity grant, in each case as described above.

**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.**

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth certain information with respect to the beneficial ownership of our ordinary shares as of April 7, 2026 for (i) the NEOs named in the Summary Compensation Table appearing elsewhere in this Amendment, (ii) each of our directors, (iii) all of our current directors and executive officers as a group, and (iv) each shareholder known by us to own beneficially more than 5% of our ordinary shares. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem ordinary shares that may be acquired by an individual or group within 60 days after April 7, 2026 pursuant to the exercise of options, the vesting of restricted share unit awards, the exercise of pre-funded warrants, or the conversion of our outstanding Series A preferred shares into ordinary shares to be outstanding for the purpose of computing the

percentage ownership of such individual or group, but such shares are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all ordinary shares shown to be beneficially owned by them based on information provided to us by these shareholders. Percentage ownership is based on 192,353,438 ordinary shares outstanding on April 7, 2026.

| Name   | Ordinary Shares Beneficially Owned |         |
|--|------------------------------------|---------|
|  | Shares                             | Percent |
| 5% Beneficial Owners   |                                    |         |
| RA Capital Management, L.P. <sup>(1)</sup>   | 34,225,506                         | 17.15%  |
| GSK plc <sup>(2)</sup>   | 18,245,691                         | 9.49%   |
| FMR LLC <sup>(3)</sup>   | 15,020,983                         | 7.81%   |
| BlackRock, Inc. <sup>(4)</sup>   | 10,017,783                         | 5.21%   |
| Adage Capital Partners, L.P. <sup>(5)</sup>  | 9,786,061                          | 5.09%   |
| Directors and Named Executive Officers   |                                    |         |
| Paul B. Bolno, M.D., MBA <sup>(6)</sup>  | 2,986,944                          | 1.53%   |
| Chandra Vargeese, Ph.D. <sup>(7)</sup>   | 1,298,439                          | *       |
| Kyle Moran, CFA <sup>(8)</sup>   | 628,193                            | *       |
| Christopher Francis, Ph.D. <sup>(9)</sup>  | 167,347                            | *       |
| Mark H. N. Corrigan, M.D. <sup>(10)</sup>  | 151,460                            | *       |
| Christian Henry <sup>(10)</sup>  | 53,230                             | *       |
| Peter Kolchinsky, Ph.D. <sup>(11)</sup>  | 34,225,506                         | 17.15%  |
| Adrian Rawcliffe <sup>(10)</sup>   | 98,230                             | *       |
| Ken Takanashi <sup>(12)</sup>  | 9,757,881                          | 5.07%   |
| Gregory L. Verdine, Ph.D. <sup>(13)</sup>  | 556,214                            | *       |
| Heidi Wagner <sup>(14)</sup>   | 153,575                            | *       |
| Aik Na Tan <sup>(10)</sup>   | 57,150                             | *       |
| All current directors and executive officers as a group (12 individuals) <sup>(15)</sup> | 50,134,169                         | 24.43%  |

\* Represents less than 1% of ordinary shares outstanding on April 7, 2026.

- (1) Based on information reported by RA Capital Management, L.P. (“RA Capital”) on Schedule 13D/A filed with the SEC on March 30, 2026. Consists of (i) 26,975,505 ordinary shares held by RA Capital Healthcare Fund, L.P. (the “Fund”), (ii) 16,115 ordinary shares and vested options to purchase 140,230 ordinary shares exercisable within 60 days after April 7, 2026 held by Dr. Peter Kolchinsky, a member of our Board, and (iii) 7,093,656 ordinary shares that the Fund beneficially owns based on the right to acquire upon exercise of pre-funded warrants. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Rajeev Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner of any securities of the Company held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the ordinary shares held by the Fund. Because the Fund has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Exchange Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Exchange Act, of any securities of the Company beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of securities reported herein. The address for RA Capital is 200 Berkeley Street, 18th Floor, Boston, MA 02116.
- (2) Based on information reported by GSK plc on Form 4 filed with the SEC on December 15, 2025. Consists of ordinary shares held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc. The address of GSK plc is 980 Great West Road, Brentford, Middlesex TW8 9GS, England.
- (3) Based on information reported by FMR LLC on Schedule 13G filed with the SEC on February 5, 2026. Consists of ordinary shares held of record by FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, Massachusetts 02210.
- (4) Based on information reported by BlackRock, Inc. on Schedule 13G filed with the SEC on December 31, 2025. Consists of ordinary shares held of record by BlackRock, Inc. The address of BlackRock, Inc. is 50 Hudson Yards New York, NY 10001.
- (5) Based on information reported by Adage Capital Partners, L.P. on Schedule 13G/A filed with the SEC on February 12, 2026. Consists of ordinary shares held of record by Adage Capital Partners GP, L.L.C. The address of Adage Capital Partners, L.P. is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
- (6) Consists of (i) 19,770 ordinary shares held by Dr. Bolno and (ii) 2,967,174 ordinary shares underlying options exercisable within 60 days of April 7, 2026 held by Dr. Bolno.
- (7) Consists of (i) 334,871 ordinary shares held by Dr. Vargeese and (ii) 963,568 ordinary shares underlying options exercisable within 60 days of April 7, 2026 held by Dr. Vargeese.
- (8) Consists of (i) 57,260 ordinary shares held by Mr. Moran and (ii) 570,933 ordinary shares underlying options exercisable within 60 days of April 7, 2026 held by Mr. Moran.

- (9) Consists of (i) 4,367 ordinary shares held by Dr. Francis and (ii) 162,980 ordinary shares underlying options exercisable within 60 days of April 7, 2026 held by Dr. Francis.
- (10) Consists of ordinary shares underlying options exercisable within 60 days of April 7, 2026.
- (11) See Footnote (1) above.
- (12) Mr. Takanashi, a member of our Board, is an executive officer of SNBL and an executive officer and director of SNBL USA. SNBL and Mr. Takanashi share voting and dispositive power with respect to such shares and may be deemed to beneficially own such shares. Based on information reported by Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) on Schedule 13D/A filed with the SEC on June 6, 2025. Consists of (i) 3,498,815 ordinary shares held by SNBL; (ii) 6,107,593 ordinary shares held by SNBL USA, Ltd. (“SNBL USA”). Also includes 11,243 ordinary shares and vested options to purchase 140,230 ordinary shares exercisable within 60 days of April 7, 2026 held by Mr. Takanashi. The address of SNBL is 2438 Miyanoura-cho, Kagoshima City, Kagoshima 891-1394, Japan; the address of SNBL USA is 2333 Seaway Boulevard, Everett, WA 98203; and the address of Mr. Takanashi is St. Luke’s Tower 28F, 8-1, Akashi-cho, Chuo-ku, Tokyo 104-0044, Japan.
- (13) Consists of (i) 252,517 ordinary shares held by Dr. Verdine and (ii) 303,697 ordinary shares underlying options exercisable within 60 days of April 7, 2026 held by Dr. Verdine.
- (14) Consists of (i) 16,115 ordinary shares held by Ms. Wagner and (ii) 137,460 ordinary shares underlying options exercisable within 60 days of April 7, 2026 held by Ms. Wagner.
- (15) Consists of (i) 5,746,342 ordinary shares underlying options exercisable within 60 days of April 7, 2026 held by our current directors and executive officers, (ii) 37,294,171 outstanding ordinary shares beneficially owned by our current directors and executive officers and entities affiliated with certain of our directors, and (iii) exercisable pre-funded warrants to purchase 7,093,656 ordinary shares, held by an entity affiliated with one of our directors.

### EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain information with respect to our 2021 Plan and 2014 Plan (together, the “Equity Compensation Plans”) in effect as of December 31, 2025.

| <b>Plan Category</b>                                       | <b>Number of Securities to be Issued upon Exercise of Options, Warrants and Rights</b> | <b>Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights</b> | <b>Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans</b> |
|--|--|--|---|
| Equity compensation plans approved by security holders     | 21,454,288 <sup>(1)</sup>  | 7.02 <sup>(2)</sup>  | 11,970,178 <sup>(3)</sup>   |
| Equity compensation plans not approved by security holders | 650,000 <sup>(4)</sup>   | 5.89 <sup>(5)</sup>  | -   |
| <b>Total</b>   | <b>22,104,288</b>  | <b>7.02</b>  | <b>11,970,178</b>   |

- (1) Consists of (i) options to purchase 19,676,871 of our ordinary shares outstanding under the Equity Compensation Plans, (ii) 287,567 of our ordinary shares subject to performance-based RSUs outstanding under the Equity Compensation Plans, and (iii) 1,489,849 of our ordinary shares subject to time-based RSUs outstanding under the Equity Compensation Plans, in each case as of December 31, 2025.
- (2) Reflects the weighted average exercise price of the options to purchase 19,676,871 of our ordinary shares outstanding under the Equity Compensation Plans, as of December 31, 2025.
- (3) Consists of 9,808,797 of our ordinary shares available for future grants under the Equity Compensation Plans, as well as 2,161,381 of our ordinary shares that remain available for sale under the ESPP, in each case as of December 31, 2025.
- (4) Consists of options to purchase 650,000 of our ordinary shares granted outside of the Equity Compensation Plans in accordance with Nasdaq Listing Rule 5635(c)(4), outstanding as of December 31, 2025. The options have a weighted average exercise price of \$5.89 per share, the closing price of our ordinary shares on the grant date.
- (5) Reflects the weighted average exercise price of the options to purchase 650,000 of our ordinary shares granted in accordance with Nasdaq Listing Rule 5635(c)(4), outstanding as of December 31, 2025.

### Item 13. Certain Relationships and Related Transactions, and Director Independence.

#### CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS

The following includes a summary of transactions since January 1, 2025 to which we have been a party, in which the amount involved in the transaction exceeded \$120,000, and in which any of our directors, executive officers or beneficial owners of more than 5% of our ordinary shares, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under, “Executive Officer and Director Compensation.” We refer to such transactions as “related party transactions” or

“related person transactions” and such persons as “related parties” or “related persons.” With the approval of our Board, we have engaged in the related party transactions described below.

### **Indemnification Agreements with Officers and Directors**

We have entered into deeds of indemnity with our directors and our executive officers. These agreements will require us to indemnify these individuals to the fullest extent permitted under Singapore law against liabilities that may arise by reason of their service to us as a result of any proceeding against them as to which they could be indemnified. These indemnification rights shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our Constitution, agreement, vote of shareholders or disinterested directors or otherwise if he or she is subsequently found to have been negligent or otherwise have breached their trust or fiduciary duties or to be in default thereof, or where the Singapore courts have declined to grant relief.

### **Agreements with GSK and its Affiliate**

On December 13, 2022, Wave Life Sciences USA, Inc. and Wave Life Sciences UK Limited, two of our direct, wholly-owned subsidiaries entered into a Collaboration and License Agreement (the “GSK Collaboration Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) (“GSK”), which became effective on January 27, 2023. Pursuant to the GSK Collaboration Agreement, we and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics. The discovery collaboration has an initial four-year research term and combines our proprietary discovery and drug development platform, PRISM™, with GSK’s unique insights from human genetics and its global development and commercial capabilities. In addition, the GSK Collaboration Agreement originally contained a global exclusive license to GSK for WVE-006, our first-in-class A-to-I(G) RNA editing candidate for alpha-1 antitrypsin deficiency, and in February 2026, we announced that we had regained full rights to WVE-006 from GSK.

Under the terms of the GSK Collaboration Agreement, we received an upfront payment of \$170.0 million, which included a cash payment of \$120.0 million and a \$50.0 million equity investment. With respect to the \$50.0 million equity investment, on December 13, 2022, we entered into a Share Purchase Agreement (the “GSK Share Purchase Agreement”) with Glaxo Group Limited (“GGL”), an affiliate of GSK, pursuant to which we sold 10,683,761 of our ordinary shares to GGL (the “GSK Shares”) at a purchase price of \$4.68 per share. In connection with the GSK Share Purchase Agreement, GGL and we agreed upon certain rights and restrictions as set forth in the Investor Agreement, dated as of January 26, 2023 (the “GSK Investor Agreement”). For a certain period of time, subject to certain conditions and limitations, we agreed to provide certain demand registration rights to GGL in order to register all or a portion of the GSK Shares purchased by GGL. We also provided GGL with certain “piggyback” registration rights for a certain period of time, subject to certain conditions and limitations, such that when we propose to register our ordinary shares for our account, GGL will have the right to include some or all of the GSK Shares in such registration. The GSK Investor Agreement also contains other customary terms and conditions of the parties with respect to the registration of GSK Shares. From January 1, 2025 to March 31, 2026, we recognized revenue of \$80.9 million under the GSK Collaboration Agreement.

### **Participation in Our Underwritten Offerings**

On December 11, 2025, we closed an underwritten public offering (the “December 2025 Offering”) in which we issued and sold (i) 18,552,632 ordinary shares at a public offering price of \$19.00 per share, and (ii) to certain investors in lieu of additional ordinary shares, pre-funded warrants to purchase up to 2,631,578 ordinary shares at a public offering price of \$18.9999 per pre-funded warrant. As a part of the December 2025 Offering, GSK plc, a 5% or greater holder of our ordinary shares, purchased 1,470,000 ordinary shares at the public offering price of \$19.00 per share.

### **Contract Research Services Provided by SNBL**

Pursuant to the terms of various contract research service agreements with SNBL, a contract research organization and one of our shareholders, and its affiliates, we paid SNBL \$4.0 million from January 1, 2025 to March 31, 2026. From January 1, 2025 to March 31, 2026, we incurred expenses of approximately \$5.9 million related to the aforementioned various service agreements.

### **Related Person Transaction Policy**

Our Board has adopted a written related person transaction policy that requires future transactions between us and any director, executive officer, holder of 5% or more of any class of our ordinary shares or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item 404 of Regulation S-K, or their affiliates, in which the amount involved is equal to or greater than \$120,000, be approved in advance by our Audit Committee, or if Audit Committee approval would be inappropriate, by another independent body of our Board. In approving or rejecting such proposed related person transaction, the committee is to consider all available information deemed relevant by the committee, including, but not limited to, the extent of the related person’s interest in the transaction and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances. The committee approves only

those transactions that, in light of known circumstances, are deemed to be in our best interests. In the event that any member of the committee is not a disinterested person with respect to the related person transaction under review, that member is excluded from the review and approval or rejection of such related person transaction; provided, however, that such committee member may be counted in determining the presence of a quorum at the meeting of the committee at which such transaction is considered. If we become aware of an existing related person transaction which has not been approved under the policy, the matter will be referred to the committee. The committee evaluates all options available, including ratification, revision or termination of such transaction. In the event that management determines that it is impractical or undesirable to wait until a meeting of the committee to consummate a related person transaction, the chair of the committee may approve such transaction in accordance with the related person transaction approval policy. Any such approval must be reported to the committee at the next regularly scheduled meeting.

### Director Independence

Our Board believes that independence is one important component of a high-functioning board capable of objective decision-making that represents the long-term interests of our shareholders and the Company. Since our initial public offering in 2015, our Board has enhanced its independence by replacing two previous directors — a founder and a representative of an investor with five directors who are independent and not affiliated with any of our principal shareholders. We further enhanced our Board’s independent leadership by appointing Christian Henry as our independent Chair. Our Board is committed to ensuring that its members reflect an appropriate level of independence in conjunction with the combination of qualifications, qualities and skills required to exercise its duties and responsibilities and serve the best interests of our Company and our shareholders. In accordance with our Corporate Governance Guidelines and Nasdaq rules, we hold executive sessions of our independent directors in conjunction with our regularly scheduled board meetings and otherwise as appropriate. In addition, our Compensation Committee meets in executive session with no members of management present, as necessary or appropriate, to address various compensation matters, including deliberations regarding our Chief Executive Officer’s performance and compensation.

Our Board has reviewed the materiality of any relationship that each of our directors has with our Company, either directly or indirectly. Based upon this review, our Board has determined that the following members of the Board are “independent directors” as defined by The Nasdaq Stock Market: Mses. Tan and Wagner, Drs. Kolchinsky and Corrigan, and Messrs. Henry, Rawcliffe and Takanashi.

Our Board believes that our directors should limit the number of other public company boards on which they serve so that they are able to devote adequate time to their duties to Wave, including preparing for and attending our board meetings. Our Corporate Governance Guidelines indicate that our directors should advise the Chair of our Board and the Chair of the Nominating and Corporate Governance Committee before accepting an invitation to serve on other publicly-traded company boards, and that any such service shall comply with our conflict of interest policies. Our Nominating and Corporate Governance Committee has reviewed our directors’ current commitments and determined that such commitments are consistent with our guidelines. Furthermore, our Board has concluded that each of the members of our Board is qualified and should continue to serve on our Board based on their contributions to our Company, and their current experience, qualifications, attributes and skills, which our Board believes each has continued to demonstrate since their respective appointments as directors. As our Company has evolved, our directors’ respective tenures with our Company, collective experiences, including sitting on other public company boards, and engagement with our Company have remained steadfast. Our Board believes that our directors continue to demonstrate their commitment and dedication, particularly as we advance towards our goal of being a commercial organization. Our Corporate Governance Guidelines are publicly available on our website at <http://ir.wavelifesciences.com/> under the heading “Corporate Governance.”

### Item 14. Principal Accountant Fees and Services.

Our independent registered public accounting firm is KPMG LLP, Boston, MA, Auditor Firm ID: 185.

The following table presents fees for professional audit services rendered by KPMG LLP for the services described in the table. Fees disclosed below include fees actually billed or expected to be billed for services pertaining to the applicable fiscal year.

|                                   | 2025 |           | 2024 |           |
|-----------------------------------|------|-----------|------|-----------|
| Audit fees <sup>(1)</sup>         | \$   | 1,703,912 | \$   | 1,739,629 |
| Audit-related fees <sup>(2)</sup> |      | -         |      | -         |
| Tax fees <sup>(2)</sup>           |      | -         |      | -         |
| All other fees <sup>(2)</sup>     |      | -         |      | -         |
| Total                             | \$   | 1,703,912 | \$   | 1,739,629 |

(1) Audit fees consist of fees for the professional services rendered for the audit of our financial statements, the audit of our internal control over financial reporting, and the review of the interim financial statements included in our quarterly reports on Form 10-Q, as well as work generally only the independent registered public accounting firm and independent Singapore and United

Kingdom auditor can reasonably be expected to provide, such as statutory audits, comfort letters, and the provision of consents in connection with the filing of registration statements and related amendments, as well as other filings.

(2) There were no audit-related, tax or other fees in 2025 or 2024.

#### **Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Public Accounting Firm**

In connection with our initial public offering, we adopted a policy under which the Audit Committee must pre-approve all audit and permissible non-audit services to be provided by the independent registered public accounting firm and independent Singapore auditor. As part of its review, the Audit Committee also considers whether the categories of pre-approved services are consistent with the rules on accountant independence of the SEC and the Public Company Accounting Oversight Board. The Audit Committee pre-approved all services performed since the pre-approval policy was adopted.

Prior to engagement of an independent registered public accounting firm and independent Singapore auditor for the next year's audit, management will submit an aggregate of services expected to be rendered during that year for each of four categories of services to the Audit Committee for approval.

1. **Audit** services include audit work rendered for the audit of our financial statements, the audit of our internal control over financial reporting, and the review of the interim financial statements included in our quarterly reports on Form 10-Q, as well as work that generally only an independent registered public accounting firm and independent Singapore and United Kingdom auditor can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards.

2. **Audit-related** services are for assurance and related services that are traditionally performed by an independent registered public accounting firm and independent Singapore auditor, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.

3. **Tax** services include all services performed by an independent registered public accounting firm's tax personnel except those services specifically related to the audit of the financial statements, and include fees in the areas of tax compliance, tax planning, and tax advice.

4. **Other fees** are those associated with services not captured in the other categories. We generally do not request such services from our independent registered public accounting firm and independent Singapore auditor.

Prior to engagement, the Audit Committee pre-approves these services by category of service. During the year, circumstances may arise when it may become necessary to engage our independent registered public accounting firm and independent Singapore auditor for additional services not contemplated in the original pre-approval. In those instances, the Audit Committee requires specific pre-approval before engaging our independent registered public accounting firm and independent Singapore auditor. The Audit Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting.

PART IV

**Item 15. Exhibits and Financial Statement Schedules.**

**Item 15(a).** The documents listed below are filed as part of this Amendment No. 1 to Annual Report on Form 10-K/A.

**Item 15(a)(1) and (2).** See Item 8 of the Original 10-K. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.

**Item 15(a)(3). Exhibits:** The exhibits listed below are filed with, or incorporated by reference in, this Amendment.

| Exhibit Number                 | Exhibit Description  | Filed with this Report | Incorporated by Reference herein from Form or Schedule | Filing Date | SEC File/Reg. Number |
|--------------------------------|--|------------------------|--|-------------|----------------------|
| 3.1                            | <a href="#">Constitution (formerly known as Memorandum of Association and Articles of Association)</a>   |                        | Amendment No. 5 to Form S-1 (Exhibit 3.2)              | 11/10/2015  | 333-207379           |
| 4.1                            | <a href="#">Form of Specimen Ordinary Share Certificate</a>  |                        | Amendment No. 3 to Form S-1 (Exhibit 4.1)              | 11/06/2015  | 333-207379           |
| 4.2                            | <a href="#">Description of Securities of the Registrant and Comparison of Shareholder Rights</a>   |                        | Form 10-K (Exhibit 4.2)                                | 02/26/2026  | 001-37627            |
| 4.3.1                          | <a href="#">Form of Pre-Funded Warrant (2022)</a>  |                        | Form 8-K (Exhibit 4.1)                                 | 06/14/2022  | 001-37627            |
| 4.3.2                          | <a href="#">Form of Pre-Funded Warrant (2024)</a>  |                        | Form 8-K (Exhibit 4.1)                                 | 9/26/2024   | 001-37627            |
| 4.3.3                          | <a href="#">Form of Pre-Funded Warrant (2025)</a>  |                        | Form 8-K (Exhibit 4.1)                                 | 12/11/2025  | 001-37627            |
| 4.4                            | <a href="#">Share Purchase Agreement by and between the Registrant and C.P. Pharmaceuticals International C.V., dated as of May 5, 2016</a>              |                        | Form 10-Q (Exhibit 10.2)                               | 08/15/2016  | 001-37627            |
| <b><u>Lease Agreements</u></b> |  |                        |  |             |                      |
| 10.1.1                         | <a href="#">Lease Agreement by and between Wave Life Sciences USA, Inc., the Registrant, and King 733 Concord LLC, dated as of April 6, 2015</a>         |                        | Form S-1 (Exhibit 10.7)                                | 10/09/2015  | 333-207379           |
| 10.1.2                         | <a href="#">First Amendment (to Lease) by and between Wave Life Sciences USA, Inc. and CPI/King 733 Concord Owner, LLC, dated as of December 9, 2020</a> |                        | Form 10-K (Exhibit 10.5.2)                             | 03/04/2021  | 001-37627            |
| 10.1.3                         | <a href="#">Second Amendment (to Lease) by and between Wave Life Sciences USA, Inc. and CPI/King 733 Concord Owner, LLC, dated as of August 8, 2022</a>  |                        | Form 10-Q (Exhibit 10.1)                               | 08/11/2022  | 001-37627            |
| 10.2.1                         | <a href="#">Lease Agreement by and between Wave Life Sciences USA, Inc. and King 115 Hartwell LLC, dated as of September 26, 2016</a>                    |                        | Form 8-K (Exhibit 10.1)                                | 01/06/2017  | 001-37627            |
| 10.2.2                         | <a href="#">First Amendment (to Lease) by and between Wave Life Sciences USA, Inc. and King 115 Hartwell LLC, dated as of December 31, 2016</a>          |                        | Form 8-K (Exhibit 10.1)                                | 01/06/2017  | 001-37627            |

### **Collaboration and License Agreements**

|        |   |                             |            |           |
|--------|---|-----------------------------|------------|-----------|
| 10.3†† | <a href="#">Collaboration and License Agreement by and between Wave Life Sciences USA, Inc., Wave Life Sciences UK Limited and GlaxoSmithKline Intellectual Property (No. 3), dated as of December 13, 2022</a> | Form 10-K<br>(Exhibit 10.3) | 03/23/2023 | 001-37627 |
| 10.4   | <a href="#">Share Purchase Agreement by and between Glaxo Group Limited and the Registrant, dated as of December 13, 2022</a>   | Form 10-K<br>(Exhibit 10.4) | 03/23/2023 | 001-37627 |
| 10.5   | <a href="#">Investor Agreement by and between Glaxo Group Limited and the Registrant, dated as of January 26, 2023</a>  | Form 10-K<br>(Exhibit 10.5) | 03/23/2023 | 001-37627 |

### **Agreements with Executive Officers and Directors**

|        |   |                              |            |            |
|--------|---|------------------------------|------------|------------|
| 10.6+  | <a href="#">Form of Deed of Indemnity by and between the Registrant and each of its directors and certain of its officers</a>       | Form S-1<br>(Exhibit 10.11)  | 10/09/2015 | 333-207379 |
| 10.7+  | <a href="#">Employment Agreement, as amended and restated, between the Registrant and Paul B. Bolno, dated as of May 8, 2020</a>    | Form 10-Q<br>(Exhibit 10.1)  | 08/10/2020 | 333-207379 |
| 10.8+  | <a href="#">Employment Agreement, as amended and restated, between the Registrant and Chandra Vargeese, dated as of May 8, 2020</a> | Form 10-Q<br>(Exhibit 10.2)  | 08/10/2020 | 333-207379 |
| 10.9+  | <a href="#">Employment Agreement between the Registrant and Christopher Francis, Ph.D., dated as of November 8, 2022</a>            | Form 10-K<br>(Exhibit 10.12) | 03/23/2023 | 001-37627  |
| 10.10+ | <a href="#">Employment Agreement, as amended and restated, between the Registrant and Kyle Moran, dated as of January 1, 2021</a>   | Form 10-K<br>(Exhibit 10.15) | 03/04/2021 | 001-37627  |
| 10.11+ | <a href="#">Non-Employee Director Compensation Policy, as amended, effective as of August 11, 2025</a>                              | Form 10-Q<br>(Exhibit 10.1)  | 11/10/2025 | 001-37627  |

### **Equity and Other Compensation Plans**

|          |   |                                |            |           |
|----------|---|--------------------------------|------------|-----------|
| 10.12+   | <a href="#">Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the "2014 Equity Plan")</a>                     | Form 10-Q<br>(Exhibit 10.1)    | 11/09/2017 | 001-37627 |
| 10.13+   | <a href="#">Wave Life Sciences Ltd. 2021 Equity Plan, as amended, (the "2021 Equity Plan") effective August 5, 2025</a>     | Form 8-K<br>(Exhibit 10.1)     | 08/11/2025 | 001-37627 |
| 10.14+   | <a href="#">Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan, as amended, effective as of August 1, 2023</a>       | Form 8-K<br>(Exhibit 10.2)     | 08/07/2023 | 001-37627 |
| 10.15.1+ | <a href="#">Form of Non-qualified Share Option Agreement under the 2014 Equity Plan, effective as of September 20, 2016</a> | Form 10-Q<br>(Exhibit 10.2)    | 11/09/2017 | 001-37627 |
| 10.15.2+ | <a href="#">Form of Non-qualified Share Option Agreement under the 2014 Equity Plan, effective as of January 1, 2018</a>    | Form 10-K<br>(Exhibit 10.23.3) | 03/01/2019 | 001-37627 |
| 10.15.3+ | <a href="#">Form of Non-qualified Share Option Agreement under the 2021 Equity Plan, effective as August 10, 2021</a>       | Form 10-K<br>(Exhibit 10.3)    | 11/10/2021 | 001-37627 |

|          |  |                                |            |            |
|----------|--|--------------------------------|------------|------------|
| 10.16.1+ | <a href="#">Form of Incentive Share Option Agreement under the 2014 Equity Plan, effective as of December 2014</a>   | Form S-8<br>(Exhibit 10.1)     | 12/17/2015 | 333-208598 |
| 10.16.2+ | <a href="#">Form of Incentive Share Option Agreement under the 2014 Equity Plan, effective as of September 20, 2016</a>  | Form 10-Q<br>(Exhibit 10.3)    | 11/09/2017 | 001-37627  |
| 10.17.1+ | <a href="#">Form of Restricted Share Unit Agreement under the 2014 Equity Plan, effective as of June 16, 2016</a>  | Form 10-Q<br>(Exhibit 10.4)    | 11/09/2017 | 001-37627  |
| 10.17.2+ | <a href="#">Form of Restricted Share Unit Agreement under the 2014 Equity Plan, effective as of January 1, 2018</a>  | Form 10-K<br>(Exhibit 10.25.2) | 03/01/2019 | 001-37627  |
| 10.17.3+ | <a href="#">Form of Restricted Share Unit Agreement under the 2014 Equity Incentive Plan, effective as of January 1, 2019</a>  | Form 10-Q<br>(Exhibit 10.1)    | 05/10/2019 | 001-37627  |
| 10.17.4+ | <a href="#">Form of Restricted Share Unit Agreement under the 2021 Equity Plan, effective as of August 10, 2021</a>  | Form 10-Q<br>(Exhibit 10.4)    | 11/10/2021 | 001-37627  |
| 10.17.5+ | <a href="#">Form of Amended and Restated 2019 Performance-Based Restricted Share Unit Agreement under the 2014 Equity Incentive Plan, effective as of March 17, 2021</a> | Form 10-Q<br>(Exhibit 10.2)    | 05/13/2021 | 001-37627  |
| 10.17.6+ | <a href="#">Form of 2021 Performance-Based Restricted Share Unit Agreement under the 2014 Equity Incentive Plan, effective as of March 17, 2021</a>                      | Form 10-Q<br>(Exhibit 10.3)    | 05/13/2021 | 001-37627  |
| 10.18.1+ | <a href="#">Form of Non-qualified Share Option Agreement for UK Participants under the 2014 Equity Plan, effective as of June 21, 2017</a>                               | Form 10-Q<br>(Exhibit 10.5)    | 11/09/2017 | 001-37627  |
| 10.18.2+ | <a href="#">Form of Non-qualified Share Option Agreement for UK Participants under the 2014 Equity Plan, effective as of January 1, 2018</a>                             | Form 10-K<br>(Exhibit 10.26.2) | 03/01/2019 | 001-37627  |
| 10.18.3+ | <a href="#">Form of Non-qualified Share Option Agreement for UK Participants under the 2021 Equity Plan, effective as of August 10, 2021</a>                             | Form 10-Q<br>(Exhibit 10.5)    | 11/10/2021 | 001-37627  |
| 10.18.4+ | <a href="#">Form of Restricted Share Unit Agreement for UK Participants under the 2021 Equity Plan, effective as of August 10, 2021</a>                                  | Form 10-Q<br>(Exhibit 10.6)    | 11/10/2021 | 001-37627  |
| 10.19.1+ | <a href="#">Form of Inducement Non-qualified Share Option Agreement, effective May 2024</a>  | Form 10-Q<br>(Exhibit 10.1)    | 08/08/2024 | 001-37627  |
| 10.19.2+ | <a href="#">Form of Inducement Restricted Share Unit Agreement, effective May 2024</a>   | Form 10-Q<br>(Exhibit 10.2)    | 08/08/2024 | 001-37627  |
| 10.20.1  | <a href="#">Open Market Sale Agreement, dated as of May 10, 2019, by and between the Registrant and Jefferies LLC</a>  | Form S-3ASR<br>(Exhibit 1.2)   | 05/10/2019 | 333-231382 |
| 10.20.2  | <a href="#">Amendment No. 1 to Open Market Sale Agreement, dated as of March 2, 2020, by and between the Registrant and Jefferies LLC</a>                                | POSASR<br>(Exhibit 1.3)        | 03/02/2020 | 333-231382 |
| 10.20.3  | <a href="#">Amendment No. 2, dated March 3, 2022, to the Open Market Sale Agreement, dated as of May</a>   | Form 8-K<br>(Exhibit 10.1)     | 03/03/2022 | 001-37627  |

[10, 2019, by and between Wave Life Sciences Ltd. and Jefferies LLC](#)

|         |  |   |                                |            |           |
|---------|--|---|--------------------------------|------------|-----------|
| 10.20.4 | <a href="#">Amendment No. 3, dated November 12, 2024, to the Open Market Sale Agreement, dated as of May 10, 2019, by and between Wave Life Sciences Ltd. and Jefferies LLC</a>                        |   | Form 10-Q<br>(Exhibit 10.1)    | 11/12/2024 | 001-37627 |
| 19.1    | <a href="#">Insider Trading Policy</a>   |   | Form 10-K<br>(Exhibit 19.1)    | 03/05/2025 | 001-37627 |
| 21.1    | <a href="#">List of Subsidiaries of the Registrant</a>   |   | Form 10-K<br>(Exhibit 21.1)    | 03/12/2018 | 001-37627 |
| 23.1    | <a href="#">Consent of Independent Registered Public Accounting Firm</a>   |   | Form 10-K<br>(Exhibit 23.1)    | 02/26/2026 | 001-37627 |
| 24.1    | <a href="#">Power of Attorney (included on signature page to the Original 10-K)</a>  |   | Form 10-K<br>(Exhibit 24.1)    | 02/26/2026 | 001-37627 |
| 31.1    | <a href="#">Certifications of Principal Executive Officer pursuant to Rule 13a-14(a)</a>   | X |                                |            |           |
| 31.2    | <a href="#">Certifications of Principal Financial Officer pursuant to Rule 13a-14(a)</a>   | X |                                |            |           |
| 32*     | <a href="#">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer and Principal Financial Officer</a> |   | Form 10-K<br>(Exhibit 32)      | 02/26/2026 | 001-37627 |
| 97.1    | <a href="#">Clawback Policy, effective as of October 2, 2023</a>   |   | Form 10-K<br>(Exhibit 97.1)    | 03/06/2024 | 001-37627 |
| 101.INS | XBRL Instance Document – The Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document   |   | Form 10-K<br>(Exhibit 101.INS) | 02/26/2026 | 001-37627 |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents   |   | Form 10-K<br>(Exhibit 101.SCH) | 02/26/2026 | 001-37627 |
| 104     | The cover page for this Amendment No. 1 to the Annual Report on Form 10-K for the year ended December 31, 2025 has been formatted in Inline XBRL   |   | Form 10-K<br>(Exhibit 104)     | 02/26/2026 | 001-37627 |

(\* ) The certification incorporated by reference as Exhibit 32 that was attached to the Original 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Wave Life Sciences Ltd. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of the Original 10-K, irrespective of any general incorporation language contained in such filing.

(+ ) Indicates management contract or compensatory plan or arrangement.

(† ) Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.

(†† ) Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[\*\*\*]”) because the identified confidential portions (i) are not material and (ii) is the type that the Registrant treats as private or confidential.

**Item 16. Form 10-K Summary.**

None.

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Amendment No. 1 to Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 30, 2026

**Wave Life Sciences Ltd.**

By: /s/ Paul B. Bolno, M.D., MBA

---

Paul B. Bolno, M.D., MBA  
President and Chief Executive Officer

**CERTIFICATION PURSUANT TO  
SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Paul B. Bolno, M.D., certify that:

1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of Wave Life Sciences Ltd.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 30, 2026

/s/ Paul B. Bolno, M.D., MBA

---

Paul B. Bolno, M.D., MBA  
*President and Chief Executive Officer*  
*(principal executive officer)*

---

**CERTIFICATION PURSUANT TO  
SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Kyle Moran, certify that:

1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of Wave Life Sciences Ltd.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 30, 2026

/s/ Kyle Moran, CFA

---

Kyle Moran, CFA  
*Chief Financial Officer*  
*(principal financial officer and*  
*principal accounting officer)*

---

